
<html lang="en"     class="pb-page"  data-request-id="c2deb3c0-e1fd-4834-8e13-f98fe387519c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01952"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof" /></meta><meta name="dc.Creator" content="Ryan R.  Davis" /></meta><meta name="dc.Creator" content="Baoli  Li" /></meta><meta name="dc.Creator" content="Sang Y.  Yun" /></meta><meta name="dc.Creator" content="Alice  Chan" /></meta><meta name="dc.Creator" content="Pradeep  Nareddy" /></meta><meta name="dc.Creator" content="Steven  Gunawan" /></meta><meta name="dc.Creator" content="Muhammad  Ayaz" /></meta><meta name="dc.Creator" content="Harshani R.  Lawrence" /></meta><meta name="dc.Creator" content="Gary W.  Reuther" /></meta><meta name="dc.Creator" content="Nicholas J.  Lawrence" /></meta><meta name="dc.Creator" content="Ernst  Schönbrunn" /></meta><meta name="dc.Description" content="The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient..." /></meta><meta name="Description" content="The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 11, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01952" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01952" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01952" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01952" /></link>
        
    
    

<title>Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01952" /></meta><meta property="og:title" content="Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0007.jpeg" /></meta><meta property="og:description" content="The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a new methodology for the large-scale production of JAK2 from mammalian cells, which enabled us to determine the first crystal structures of JAK2 bound to these drugs and derivatives thereof. Along with biochemical and cellular data, the results provide a comprehensive view of the shape complementarity required for chiral and achiral inhibitors to achieve highest activity, which may facilitate the development of more effective JAK2 inhibitors as therapeutics." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a new methodology for the large-scale production of JAK2 from mammalian cells, which enabled us to determine the first crystal structures of JAK2 bound to these drugs and derivatives thereof. Along with biochemical and cellular data, the results provide a comprehensive view of the shape complementarity required for chiral and achiral inhibitors to achieve highest activity, which may facilitate the development of more effective JAK2 inhibitors as therapeutics." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0007.jpeg" /></meta><meta name="twitter:title" content="Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01952"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01952">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01952&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01952&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01952&amp;href=/doi/10.1021/acs.jmedchem.0c01952" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 2228-2241</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01968" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02019" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ryan R. Davis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan R. Davis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+R.++Davis">Ryan R. Davis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Baoli Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baoli Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baoli++Li">Baoli Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sang Y. Yun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sang Y. Yun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sang+Y.++Yun">Sang Y. Yun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alice Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alice Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alice++Chan">Alice Chan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pradeep Nareddy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pradeep Nareddy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pradeep++Nareddy">Pradeep Nareddy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven Gunawan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Gunawan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Gunawan">Steven Gunawan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Muhammad Ayaz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Muhammad Ayaz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad++Ayaz">Muhammad Ayaz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harshani R. Lawrence</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harshani R. Lawrence</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harshani+R.++Lawrence">Harshani R. Lawrence</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9263-7775" title="Orcid link">http://orcid.org/0000-0002-9263-7775</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary W. Reuther</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary W. Reuther</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Oncology Department, Moffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary+W.++Reuther">Gary W. Reuther</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicholas J. Lawrence</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicholas J. Lawrence</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+J.++Lawrence">Nicholas J. Lawrence</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ernst Schönbrunn</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ernst Schönbrunn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#ec899e829f98c29f8f8483828e9e998282ac81838a8a859898c2839e8b"><span class="__cf_email__" data-cfemail="adc8dfc3ded983decec5c2c3cfdfd8c3c3edc0c2cbcbc4d9d983c2dfca">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ernst++Sch%C3%B6nbrunn">Ernst Schönbrunn</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3589-3510" title="Orcid link">http://orcid.org/0000-0002-3589-3510</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01952&amp;href=/doi/10.1021%2Facs.jmedchem.0c01952" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 2228–2241</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 November 2020</li><li><span class="item_label"><b>Published</b> online</span>11 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01952" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01952</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2228%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRyan%2BR.%2BDavis%252C%2BBaoli%2BLi%252C%2BSang%2BY.%2BYun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01952%26title%3DStructural%2BInsights%2Binto%2BJAK2%2BInhibition%2Bby%2BRuxolitinib%252C%2BFedratinib%252C%2Band%2BDerivatives%2BThereof%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2241%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01952"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1421</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01952" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;R. Davis&quot;},{&quot;first_name&quot;:&quot;Baoli&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Sang&quot;,&quot;last_name&quot;:&quot;Y. Yun&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Pradeep&quot;,&quot;last_name&quot;:&quot;Nareddy&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Gunawan&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Ayaz&quot;},{&quot;first_name&quot;:&quot;Harshani&quot;,&quot;last_name&quot;:&quot;R. Lawrence&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;W. Reuther&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;J. Lawrence&quot;},{&quot;first_name&quot;:&quot;Ernst&quot;,&quot;last_name&quot;:&quot;Schönbrunn&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2228-2241&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01952&quot;},&quot;abstract&quot;:&quot;The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a new methodology for the large-scale production of JAK2 from mammalian cells, which enabled us to determine the first crystal structures of JAK2 bound to these drugs and derivatives thereof. Along with biochemical and cellular data, the results provide a comprehensive view of the shape complementarity required for chiral and achiral inhibitors to achieve highest activity, which may facilitate the development of more effective JAK2 inhibitors as therapeutics.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01952&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01952" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01952&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01952" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01952&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01952" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01952&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01952&amp;href=/doi/10.1021/acs.jmedchem.0c01952" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01952" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01952" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01952%26sid%3Dliteratum%253Aachs%26pmid%3D33570945%26genre%3Darticle%26aulast%3DDavis%26date%3D2021%26atitle%3DStructural%2BInsights%2Binto%2BJAK2%2BInhibition%2Bby%2BRuxolitinib%252C%2BFedratinib%252C%2Band%2BDerivatives%2BThereof%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D2228%26epage%3D2241%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Volume 64, Issue 4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Volume 64, Issue 4"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a new methodology for the large-scale production of JAK2 from mammalian cells, which enabled us to determine the first crystal structures of JAK2 bound to these drugs and derivatives thereof. Along with biochemical and cellular data, the results provide a comprehensive view of the shape complementarity required for chiral and achiral inhibitors to achieve highest activity, which may facilitate the development of more effective JAK2 inhibitors as therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinases have become one of the most desired classes of drug targets given their crucial roles in the regulation of cellular proliferation, survival, signaling, metabolism, and homeostasis. As a mediator of cytokine receptor activation, Janus kinase 2 (JAK2) is a cytosolic tyrosine kinase that phosphorylates signal transducer and activator of transcription proteins (STATs) resulting in SH2-domain mediated dimerization and STAT activation. STATs govern many processes including cell proliferation, differentiation, and immunological responses vital for cell survival.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The JAK/STAT pathway has been listed as one of the 12 core cancer pathways demonstrating the importance of proper JAK2 regulation to maintain a normal cell function.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> JAK2 is a multidomain protein (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Figure S1</a>), which undergoes <i>trans</i>-autophosphorylation on the activation loop of the kinase domain (KD) involving residues Tyr1007 and Tyr1008. The purpose of this phosphorylation is not fully known but is thought to aid in the recruitment and phosphorylation of STATs.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Type 1 inhibitors have been shown to bind to the adenosine triphosphate (ATP) binding site of the active conformation of JAK2, but inhibition paradoxically leads to accumulation of phosphorylated residues on the activation loop with increasing inhibitor concentration.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> This phenomenon has been attributed to the protection of activation loop phosphotyrosines from phosphatases.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Higher levels of phosphorylated Tyr1007/1008, and therefore higher levels of constitutively active JAK2, have also been shown to be caused by a single hyperactivating point mutation, V617F, found in the pseudokinase domain (PKD) of JAK2.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p last">Constitutively active JAK2 has been identified in several types of cancers including breast cancer, lymphomas, and myeloid malignancies.<a onclick="showRef(event, 'ref3 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref8 ref9 ref10">(3,8−10)</a> The V617F mutation is the most commonly identified mutation found in myeloproliferative neoplasms (MPNs), in more than 95% of polycythemia vera patients and in more than 50% of all thrombocythemia and primary myelofibrosis cases.<a onclick="showRef(event, 'ref8 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref11">(8,11)</a> The Food and Drug Administration (FDA) approved the pyrrolopyrimidine JAK2 inhibitor ruxolitinib in 2011 and the dianilinopyrimidine inhibitor fedratinib in 2019 for treating myelofibrosis.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Baricitinib, an achiral analogue of ruxolitinib, was approved for rheumatoid arthritis in 2018.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> JAK2 inhibitors for MPN provide quality of life improvements but little efficacy at antagonizing the natural course of disease. To date, no crystal structure of ruxolitinib has been reported with any of the JAK family proteins, making ruxolitinib the oldest FDA-approved kinase inhibitor without a cocrystal structure with its target protein.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Likewise, structural information on the interaction of JAK2 with fedratinib and baricitinib remains unknown. Knowledge of these structures, however, is required for the development of more efficacious drugs to specifically target aberrant JAK2. Here, we report the first crystal structures of ruxolitinib, fedratinib, and baricitinib along with derivatives bound to the JAK2 KD. We introduce a new methodology to efficiently produce crystallization-grade JAK2 KD from mammalian cells, which enabled efficient structure–activity relationship (SAR) studies with inhibitors of different chemical scaffolds. A total of 14 high-resolution crystal structures were determined of JAK2 liganded with known and novel inhibitors. The data sets detail the requirements of small molecule inhibitors for shape complementarity with the ATP site of JAK2 and provide a structural basis for the stereoselective discrimination of enantiomers of ruxolitinib and derivatives thereof.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Ruxolitinib Significantly Increases the Stability of JAK2 KD Overexpressed in Expi293F Cells</h3><div class="NLM_p">Previously, JAK2 KD had been predominantly purified from insect cells; however, this process takes several weeks to generate and amplify the baculovirus to produce large enough quantities of purified protein. Upon transient expression of JAK2 KD in Expi293F cells, the presence of ruxolitinib during the transfection increased the levels of phosphorylated JAK2 (pY1007), as previously reported,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> as well the overall amount of JAK2 KD in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Protein levels of recombinant JAK2 KD from Expi293F cells were approximately 60-fold higher with 1 μM ruxolitinib compared to untreated cells. Additionally, by including histone deacetylase (HDAC) inhibitors, valproic acid or butyric acid, during expression alongside ruxolitinib, JAK2 KD levels increased fourfold over that of ruxolitinib alone (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ruxolitinib enhances the expression and purification of crystallization-grade JAK2 KD. (A) Expi293F cells were transiently transfected with wild-type JAK2 KD. Cells were treated with increasing concentrations of ruxolitinib during the 24-hour transfection. Cell lysates were subjected to immunoblotting to detect phosphorylated and unphosphorylated JAK2 KD along with the loading control GAPDH. Densitometry of the western blot is depicted as a bar graph. (B) Same as (A) except 2 mM and 4 mM butyric acid (BA) or valproic acid (VPA) were added to cells with 1 μM ruxolitinib. (C) Expi293F cells were transiently transfected with JAK2 KD +/– 1 μM ruxolitinib and analyzed by CETSA. Cells were incubated at the indicated temperatures for 3 min, and lysates were probed for JAK2 KD and the loading control actin. The graph shows the densitometry values relative to the loading control as a function of temperature. Data were fit to a four-parameter Hill equation, yielding EC<sub>50</sub> values of 45 and 47 °C for JAK2 KD expressed in the absence and presence of ruxolitinib, respectively. (D) Cells were grown as in (C) for ITDR against ruxolitinib at 47 °C for 3 min, and cell lysates were probed for JAK2 and GAPDH. The corresponding densitometry values were fit to a four-parameter Hill equation yielding EC<sub>50</sub> = 3.8 μM. (E) SDS-PAGE of typical purification of JAK2 KD from 1 L of Expi293F cell culture grown in the presence of 1 μM ruxolitinib and 4 mM BA for 24 h. Lane 1 GenScript broad range ladder, Lane 2 soluble lysate, Lane 3 GE HisTrap flow-through, Lane 4 GE HisTrap elution peak, and Lane 5 GE S75 elution peak. (F) Photograph of X-ray-grade crystals grown from thus purified JAK2 KD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Next, we investigated the thermostability of JAK2 KD upon transient expression in the presence of ruxolitinib using a cellular thermal shift assay (CETSA)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and isothermal dose response (ITDR). At 1 μM concentration, ruxolitinib elevated the cellular thermostability of JAK2 KD by 2 °C, from 45 to 47 °C (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). At 47 °C, the amount of expressed JAK2 KD increased in dose-response with ruxolitinib (EC<sub>50</sub> = 3.8 μM) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D). Expression in the absence of ruxolitinib yielded very little soluble protein and purity could not be achieved above 50% (data not shown). Adding ruxolitinib to cells during transfection resulted in significantly more protein, which could be purified to homogeneity using Ni-affinity and size-exclusion chromatography with yields of 3 mg/L culture (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>E). Purified JAK2 KD yielded X-ray grade crystals within 24 h (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>F).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> SAR Studies of Diverse Small Molecule JAK2 Inhibitors</h3><div class="NLM_p">To assess the suitability of purified JAK2 KD for SAR studies for drug development campaigns, three series of JAK2 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A-C) were subjected to binding studies by differential scanning fluorimetry (DSF). Series A consists of ruxolitinib enantiomers and FDA-approved derivatives baricitinib and tofacitinib, while series B consists of piperidine–aniline analogues of ruxolitinib. Series C comprises the FDA-approved JAK2 inhibitor fedratinib and other diaminopyrimidines, which were further developed as dual JAK2–BRD4 inhibitors from early lead compounds.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The melting temperature of JAK2 in the absence of an inhibitor was 50 °C, and thermal shifts in the presence of a 100 μM inhibitor ranged from 3.3 to 5.5 °C for series A, 6.4 to 12 °C for series B, and 2.2 to 5.2 °C for series C (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Purified JAK2 KD from Expi293 cells is suitable for SAR studies by DSF. Three series of JAK2 inhibitors were subjected to SAR studies: (A) Ruxolitinib stereoisomers and FDA-approved derivatives, (B) piperidine–phenylamine analogues of ruxolitinib, and (C) fedratinib and derived dual JAK2–BRD4 inhibitors. (D) DSF derivative plots of JAK2 KD in the absence (DMSO) and presence of 100 μM inhibitor. (E) Viability of UKE-1 cells in response to increasing inhibitor concentration. (F) DSF and biochemical enzyme inhibition data correlate significantly. (G) Analysis of DSF and UKE-1 cell growth inhibition data shows high correlation for series A, but not for series B and C. Series B likely suffers from poor cell permeability. (H) For series C, cell inhibition data correlate significantly with the binding potential for BRD4-1, suggesting a predominant activity through inhibition of BRD4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding and Inhibitory Potential of Investigated JAK2 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">series</th><th class="colsep0 rowsep0" align="center">compound ID</th><th class="colsep0 rowsep0" align="center">binding potential<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">biochemical inhibition<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">UKE-1 cell growth inhibition<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Δ<i>T</i><sub>m</sub> (°C)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">Ruxolitinib</td><td class="colsep0 rowsep0" align="left">5.5 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.40 ± 0.005</td><td class="colsep0 rowsep0" align="left">0.1 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-Ruxolitinib</td><td class="colsep0 rowsep0" align="left">3.3 ± 0.04</td><td class="colsep0 rowsep0" align="left">5.0 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.04 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(rac)-Ruxolitinib</td><td class="colsep0 rowsep0" align="left">4.8 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.92 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Baricitinib</td><td class="colsep0 rowsep0" align="left">5.2 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.13</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Tofacitinib</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.08</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.39</td><td class="colsep0 rowsep0" align="left">0.91 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left"><i>(R)</i>-1</td><td class="colsep0 rowsep0" align="left">12 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.03</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>(S)</i>-1</td><td class="colsep0 rowsep0" align="left">8.3 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.099 ± 0.02</td><td class="colsep0 rowsep0" align="left">6.3 ± 5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>(rac)-1</i></td><td class="colsep0 rowsep0" align="left">11.8 ± 0.05</td><td class="colsep0 rowsep0" align="left">< 0.05</td><td class="colsep0 rowsep0" align="left">2.2 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">7 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.048</td><td class="colsep0 rowsep0" align="left">4.5 ± 5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">6.4 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.62 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">Fedratinib</td><td class="colsep0 rowsep0" align="left">5.2 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.39</td><td class="colsep0 rowsep0" align="left">0.66 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.09</td><td class="colsep0 rowsep0" align="left">6.5 ± 3.5</td><td class="colsep0 rowsep0" align="left">0.2 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.04</td><td class="colsep0 rowsep0" align="left">8.2 ± 5.7</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">2.2 ± 0.06</td><td class="colsep0 rowsep0" align="left">11.4 ± 0.87</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.05</td><td class="colsep0 rowsep0" align="left">3.6 + 1.1</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Standard deviation (SD) from two DSF data sets, each performed in quadruplicate.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SD from two data sets of radiometric assay by Reaction Biology.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Standard error of the mean (SEM) for data from three experiments, each performed in hexaplicate.</p></div></div></div><div class="NLM_p last">To evaluate if the thermal shifts reflect the inhibitory activity against JAK2 in cells, compounds were characterized for growth inhibitory activity of UKE-1 cells, which are driven by V617F mutant JAK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The resulting IC<sub>50</sub> values ranged from 0.1 to 1.0 μM for series A, 0.6 to 6.3 μM for series B, and 0.15 to 0.66 μM for series C. Additionally, compounds were characterized for inhibition of the enzymatic JAK2 activity using a radiometric assay by Reaction Biology Corp., with IC<sub>50</sub> values ranging from 0.29 to 5.0 nM for series A, 0.05 to 0.26 nM for series B, and 0.75 to 11.4 nM for series C (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Statistical significance of the data sets was evaluated using Pearson’s correlation analyses (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F-H). Thermal shifts showed excellent correlation with enzymatic inhibition values across all compounds, except for <i>(R)</i>-<b>1</b> and <i>rac</i>-<b>1</b> of series B, the high inhibitory activity of which likely exceeded the sensitivity of the radiometric assay applied (IC<sub>50</sub> < 0.15 nM) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F). By contrast, only series A showed significant correlation with the cellular inhibition data (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>G). Series B probably suffered from poor cell permeability, while series C showed a higher cell growth inhibitory activity than expected from JAK2 inhibition alone. The increased cellular activity of series C is likely caused by their dual activity against JAK2 and BRD4 as UKE-1 cells are highly sensitive to the inhibition of BRD4.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The thermal shifts exerted by these compounds toward BRD4 correlated significantly with the inhibitory activity against UKE-1 cell growth (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>H).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structural Basis of JAK2 Inhibition by Ruxolitinib and Baricitinib</h3><div class="NLM_p">Structural information on the JAK2–ruxolitinib complex was previously limited to molecular dynamics simulations<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> or predictions based on the known structures of c-SRC with ruxolitinib<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and of JAK2 with tofacitinib.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Crystals of JAK2 KD grown in the absence of an added inhibitor (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>F) showed that ruxolitinib was still bound to protein despite ∼100,000-fold dilution throughout the purification process, reflecting the high binding affinity of ruxolitinib to JAK2 KD. However, bound ruxolitinib could be readily displaced by other inhibitors through in-diffusion of crystals with 1 mM inhibitor for 72 h prior to data collection. Ruxolitinib was housed deep inside the ATP site, anchored through H-bonding interactions between the pyrrolopyrimidine moiety and main chain atoms of Glu930 and Leu932 of the hinge region (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A-D).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis of ruxolitinib interaction with JAK2. Cocrystal structure of JAK2 KD liganded with ruxolitinib determined at 1.9 Å resolution (PDB 6VGL). (A) Electrostatic surface potential of the JAK2–ruxolitinib complex. The inhibitor is shown as yellow spheres. (B) Positioning of ruxolitinib in the ATP site. The hinge region is shown in orange, gatekeeper residue in red, DFG motif in green, P-loop in cyan, C-helix in magenta, and other residues in grey. (C) Binding interactions of ruxolitinib in the ATP site. Potential H-bonding and hydrophobic vdW interactions are indicated as black and green dotted lines, respectively. (D) 2Fo–Fc electron density map (1σ) of bound ruxolitinib at 1.9 Å resolution. (E) Binding pose of ruxolitinib (beige) in c-SRC (PDB 4U5J) and upon superposition with ruxolitinib in JAK2 (yellow). (F) 1.9 Å resolution cocrystal structure of JAK2 with baricitinib (magenta, PDB 6VN8) and superposition with ruxolitinib (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The inhibitor was held in place through several van der Waals (vdW) hydrophobic interactions with surrounding residues, including the P-loop (Leu855 and Gly856) and the DFG motif (Asp994). The binding pose of ruxolitinib in JAK2 agrees with molecular docking predictions<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> but significantly differs from that observed in the crystal structure of c-SRC (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In SRC, ruxolitinib is rotated ∼180° relative to the hinge region, likely caused by repulsion and/or steric hindrance with the gatekeeper residue Thr338. In JAK2, the hydrophobic and flexible gatekeeper residue Met929 accommodates ruxolitinib through multiple vdW interactions. Accordingly, ruxolitinib inhibitory activity is three orders of magnitudes higher for JAK2 over SRC.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> To confirm the pyrrolopyrimidine binding mode of ruxolitinib in JAK2, a cocrystal structure was determined with baricitinib showing almost identical positioning of the two inhibitors in the ATP site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>F).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Stereoselective Discrimination of Ruxolitinib and Aniline Derivatives by JAK2</h3><div class="NLM_p">The high diffraction power of the JAK2 KD crystals prompted us to evaluate the SAR of enantiomers of ruxolitinib and analogues thereof. The (<i>S</i>)-isomer of ruxolitinib is ∼10-fold less active against JAK2 than the (<i>R</i>)-isomer (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The cocrystal structure revealed that (<i>S</i>)-ruxolitinib adopts a binding pose similar to (<i>R</i>)-ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) and achieves shape complementarity with the ATP site through ∼180° rotation about the chiral center (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Using the racemic mixture of ruxolitinib, (<i>rac</i>)-ruxolitinib, the resulting cocrystal structure exclusively revealed the (<i>R</i>)-isomer bound (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Likewise, the (<i>R)</i>- and (<i>S)</i>-enantiomers of aniline derivatives of ruxolitinib, (<i>R</i>)-<b>1</b> and (<i>S</i>)-<b>1</b>, assumed the same orientation for the cyclopentyl and propionitrile moieties in the ATP site (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D-F). Furthermore, the racemic mixture (<i>rac</i>-<b>1</b>) showed only the (<i>R</i>)-isomer bound (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>G). The data demonstrate that JAK2 discriminates between the (<i>R</i>)- and (<i>S</i>)-stereoisomers of ruxolitinib and derivatives by preferentially interacting with the (<i>R</i>)-isomer. Ruxolitinib derivatives devoid of a chiral center and the cyclopentyl group (<b>2</b> and <b>3</b>) exhibited the same preference of the respective propionitrile and butenyl moieties for positioning in the subpocket that accommodates the propionitrile of ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>H,I). Notably, the aniline derivatives interacted in the ATP site through an additional H-bond with the hinge region (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D-I), which explains the substantial increase in the JAK2 inhibitory activity of series B over ruxolitinib and series A (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. JAK2 discriminates between the (<i>R</i>)<i>-</i> and (<i>S</i>)-stereoisomers of ruxolitinib and derivatives thereof. Distinct stereoisomers and the enantiomeric mixture of ruxolitinib and derivatives were subjected to crystallographic studies with JAK2 KD. (A) Cocrystal structure of (<i>S</i>)-ruxolitinib (PDB 6VSN). (B) Superposition of the (<i>R</i>)- and (<i>S</i>)-isomers of ruxolitinib (yellow and cyan, respectively) reveals that (<i>S</i>)-ruxolitinib adopts shape complementarity with the ATP site through ∼180° rotation about the stereocenter. (C) Cocrystal structure obtained with the racemic mixture of ruxolitinib, (<i>rac</i>)-ruxolitinib (PDB 6VNK) reveals only the (<i>R</i>)-isomer bound (green). The inset shows the superposition of (<i>rac</i>)-ruxolitinib with ruxolitinib. (D) Cocrystal structure showing the H-bonding interactions of (<i>R</i>)-<b>1</b> (yellow, PDB 6VNC) with the hinge region. (E) Same as (D) for the (<i>S</i>)<i>-</i><b>1</b> (cyan, PDB 6VNB). (F) Superposition of (<i>R</i>)-<b>1</b> and (<i>S</i>)-<b>1</b> reveals the same adaptation as for ruxolitinib (B). (G) Cocrystal structure obtained with (<i>rac</i>)-<b>1</b> (green, PDB 6VS3) shows only the (<i>R</i>)-isomer bound. The inset shows the superposition of (<i>rac</i>)-<b>1</b> with (<i>R</i>)-<b>1</b> (yellow). (H) Cocrystal structure with derivative <b>2</b> devoid of a stereocenter (PDB 6VNJ) reveals the same binding pose and inhibitor conformation as (<i>R</i>)-<b>1</b>. (I) Same as (H) for derivative <b>3</b> (PDB 6VNM). The blue mesh is the 2Fo–Fc electron density of ligand contoured at 1σ. The electron density maps upon refinement omitting the ligand are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Figure S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structural Basis of JAK2 Inhibition by Diaminopyrimidines</h3><div class="NLM_p">To further probe the ATP site, cocrystal structures were determined with dianilinopyrimidine-containing inhibitors of series C. All inhibitors interacted with the hinge region similarly to the aniline derivatives of ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Diaminopyrimidine inhibitors mimic the binding pose of ruxolitinib–aniline derivatives. (A) Cocrystal structure of JAK2 with fedratinib (PDB 6VNE). The inset shows the superposition of fedratinib (yellow) with (<i>R</i>)-<b>1</b> (magenta). (B) Cocrystal structure with <b>4</b> (PDB 6VNG). The inset shows the superposition of <b>4</b> (yellow) with fedratinib (green). (C) Cocrystal structure with <b>5</b> (PDB 6VNH). (D) Cocrystal structure with <b>6</b> (PDB 6VNL). (E) Cocrystal structure with <b>7</b> (PDB 6VNF).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, the lack of a pyrrolo moiety allows only for the establishment of H-bonds with the main chain atoms of Leu932, but not with Glu930. This is reflected by the 10-fold reduced biochemical potency of inhibitors of series C against JAK2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Reversal of the sulfonamide moiety and addition of fluorine (<b>4</b>), which are beneficial for binding to the acetyl-lysine binding site of BRD4,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> slightly tilted the aniline ring such that the <i>tert-</i>butyl moiety moves away from Val863 and positions close to the carboxyl group of Asp994 of the DFG motif (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Although the reversed sulfonamide forms potential H-bonds with the side chain of Asn981, the unfavorably close distance between the hydrophobic <i>tert-</i>butyl and Asp994 may contribute to the observed slight reduction in inhibitory activity of <b>4</b> and related compounds <b>5</b> and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Constraining the sulfonamide moiety using an indoline moiety (<b>7</b>) was well tolerated (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E) and showed the highest inhibitory activity against JAK2 across series C (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">JAK2 presents challenges for structural studies as it is not stable upon recombinant overexpression, and typical protein purification requires over 10 L of insect cultures from bioreactors to obtain a few milligrams of crystallization-grade protein.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23−26)</a> Recombinant overexpression of JAK2 KD using mammalian Expi293F cells requires only 24 h of growth post-transfection, and 1 L of culture is sufficient to purify milligram quantities of crystallization-grade protein for biochemical and structural studies. This was achieved using ruxolitinib during expression, which significantly enhanced protein stability and purification yields and enabled the first crystal structures of JAK2 to be determined from protein expressed in mammalian cells. The crystal structure data suggest that ruxolitinib improves the thermostability of JAK2 by decreasing flexible regions and forming a more rigid structure with well-defined activation and P-loops. Notably, ruxolitinib did not affect the proliferation of Expi293F or HEK293 cells even at 10 μM after 72 h.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This strategy provided faster, more efficient, and cost-effective production of recombinant JAK2 and may be applicable to other difficult to overexpress kinases provided that the inhibitor is specific, potent, and nonlethal over the timeframe of expression.</div><div class="NLM_p">Robust crystallization conditions and ease of in-diffusion of inhibitors resulted in 14 novel cocrystal structures of JAK2 liganded with various inhibitors of three chemical scaffolds. Along with binding and inhibition data, this information provides a comprehensive view of the ATP site and the shape complementarity required for small molecules to achieve highest inhibitory activity. The (<i>R</i>)- and (<i>S</i>)-stereoisomers of ruxolitinib and aniline derivatives thereof were thoroughly characterized for their binding potential and inhibitory activity against cancer cells driven by constitutively active V617F JAK2. While (<i>S</i>)<i>-</i>ruxolitinib is a formidable inhibitor of JAK2 (IC<sub>50</sub> = 5 nM), the (<i>R</i>)-isomer exerted a > 10-fold higher activity with respect to binding and cell kill potential. Cocrystal structures obtained with the isolated isomers along with racemic mixtures demonstrate that JAK2 discriminates against the (<i>S</i>)-configuration. The (<i>S</i>)-isomer mimics the conformation of the preferred (<i>R</i>)-isomer through rotation about the chiral center, but the resulting binding pose is less compatible with the ATP site. Notably, the achiral analogue baricitinib adopts a conformation almost identical to that of ruxolitinib, which is reflected in the similar values obtained for binding, enzymatic, and cellular activities of these FDA-approved inhibitors.</div><div class="NLM_p last">Piperidine–aniline derivatives of both (<i>R</i>)- and (<i>S</i>)-ruxolitinib showed greatly enhanced binding and inhibitory potential toward JAK2; the picomolar activities could not be resolved by the steady-state assays employed here. This substantial increase in inhibitory activity is attributed to an additional H-bond established with the hinge region. Although these compounds suffer from poor cell penetration as indicated by a significant loss of the cell inhibitory activity, solubilizing groups other than piperidine may alleviate this drawback. Diaminopyrimidine inhibitors of JAK2, including fedratinib, mimic the binding pose of aniline derivatives of ruxolitinib. However, they lack the potential to establish an H-bond with Glu930 of the hinge region, which is reflected by the reduced but still formidable inhibitory activities (IC<sub>50</sub> between 0.75 and 11.4 nM). These compounds also inhibit BET bromodomains to varying degrees and appear to exert a strong cell growth inhibitory activity by predominantly targeting BRD4. Previously, structural modeling, binding, and enzymatic assays using full-length JAK2 expressed in insect cells showed high affinity of fedratinib for the substrate-binding site.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The cocrystal structure of JAK2 KD with fedratinib (or any other compound studied herein) showed that the inhibitor bound exclusively to the ATP site. It is conceivable that fedratinib interaction with the substrate-binding site occurs in the full-length enzyme, but not in the isolated KD. Combined, our findings may help the iterative drug design process for developing JAK2 inhibitors with increased efficacy to combat cancers caused by this enzyme.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Compounds and Reagents</h3><div class="NLM_p last">Reagents for biochemical and crystallographic experiments were purchased from Fisher Scientific and Hampton Research unless otherwise indicated. Ruxolitinib (phosphate) was purchased from LC Laboratories (R-6688, >99%), tofacitinib (citrate) from MedChemExpress (HY-40354A, 99.1%), baricitinib (free base) from Combi-Blocks (QJ-1094, 98%), and fedratinib from MedChemExpress (HY-10409, 99.9%). The following antibodies were used for immunoblotting: His-HRP (ProteinTech, HRP-66005, 1:5000), pJAK2 (Y1007/1008) (Cell Signaling, 3771, 1:1000), actin (Sigma, A5441, 1:1000), GAPDH-HRP (ProteinTech, HRP-60004, 1:10,000), and anti-mouse-HRP IgG (Jackson ImmunoResearch, 115-035-003, 1:2000).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Synthetic Methods</h3><div class="NLM_p last">All reagents were purchased from commercial suppliers and used without further purification. <sup>1</sup>H nuclear magnetic resonance (NMR) spectra were recorded using a Bruker 500 MHz spectrometer with CDCl<sub>3</sub>, CD<sub>3</sub>OD, or DMSO<b>-</b><i>d</i><sub>6</sub> as the solvent. <sup>13</sup>C NMR spectra were recorded at 125 MHz. All coupling constants were measured in Hertz (Hz), and the chemical shifts (δ<sub>H</sub> and δ<sub>C</sub>) were quoted in parts per million (ppm) relative to TMS (δ 0), which was used as the internal standard. High-resolution mass spectroscopy was carried out using an Agilent 6210 LC/MS (ESI<b>-</b>TOF). High-performance liquid chromatography–mass spectrometry (HPLC-MS) analysis was performed using an Agilent 6120 single-quadrupole 1220 LC/MS equipped with a Zorbax SB-C18 column (4.6 × 50 mm, 1.8 μm). The purity of final compounds that underwent biological assessment was >95% as measured by HPLC-MS. Thin-layer chromatography (TLC) was performed using silica gel 60 F254 plates (Fisher), with observation under UV when necessary. Anhydrous solvents (acetonitrile, dimethylformamide, ethanol, isopropanol, methanol, and tetrahydrofuran) were used as purchased from Aldrich. Burdick and Jackson HPLC-grade solvents (methanol, acetonitrile, and water) were purchased from VWR for HPLC and high-resolution mass analysis. HPLC-grade trifluoroacetic acid (TFA) was purchased from Fisher. Compound synthesis and characterization are detailed in the Supporting Information.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Compound Synthesis and Characterization</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Pyrrolopyrimidine Inhibitors of JAK2</h4><div class="NLM_p last">(<i>S</i>)-Ruxolitinib was prepared by a novel resolution of pyrazole-containing carboxylic acid <b>9</b> (from conjugate addition of 4-bromo-1<i>H</i>-pyrazole and ester hydrolysis of <b>8</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>) as shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Scheme S1</a>. Reaction of <b>9</b> with the Evans oxazolidinone provided the diastereoisomeric oxazolidinones (4<i>R,</i>3<i>R</i>)-<b>10</b> and (4<i>R,</i>3<i>S</i>)-<b>10</b>, which were easily separated to homogeneity by flash chromatography on a silica gel. The faster-running fraction was identified as (4<i>R,</i>3<i>S</i>)-<b>10</b> by correlation to the enantiomer of clinically used (<i>R</i>)-ruxolitinib using the synthetic route described in a reported patent.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Treatment of (4<i>R,</i>3<i>S</i>)-<b>10</b> with ammonium hydroxide<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> gave the primary amide <b>11</b>, which upon dehydration with phosphorus pentoxide gave the nitrile <b>12</b>. Formation of the boronate ester <b>13</b> followed by a Suzuki reaction with 4-bromo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine provided (<i>S</i>)-ruxolitinib. The enantiomeric excess of (<i>S</i>)-ruxolitinib was determined to be >99.99% by chiral HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Figure S3</a>). A sample of (<i>rac</i>)-ruxolitinib was prepared from <i>rac</i>-<b>13</b> in the same way. The synthesis of the ruxolitinib analogues (<i>R</i>)- and (<i>S</i>)-<b>1</b> is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Schemes S1,S2</a>. 2-Chloro-ruxolitinib (<b>14</b>) was prepared by Suzuki coupling of <b>13</b> with 2,4-dichloropyrrolopyrimidine (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Scheme S1</a>). Substitution of the chlorine atom with the anilinopyrimidine substituent required protection of the pyrrole NH group. Thereby, Buchwald–Hartwig amination of the boc-protected pyrrolopyrimidine <b>15</b> gave <b>16</b> bearing anilinopiperidine at the 2-position of the pyrimidine ring. Finally, removal of the protecting groups gave the desired (<i>S</i>)-<b>1</b> bearing the required piperidine group oriented toward the solvent-accessible region. Again, a chiral HPLC analysis indicated that the enantiomeric excess of (<i>S</i>)-<b>1</b> was >99.99% (as determined by the e.e. of its <i>bis</i>-boc protected precursor (<i>S</i>)-<b>16</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Figure S4</a>). The enantiomer (<i>R</i>)-<b>1</b> was prepared in the same way using the diastereoisomer (<i>4R,3R</i>)-<b>10</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Scheme S2</a>). In this case, the enantiomeric excess of (<i>R</i>)-<b>1</b> was 98.6% (as determined by the e.e. of its <i>bis</i>-boc protected precursor (<i>R</i>)-<b>22</b>. Ruxolitinib derivatives lacking the cyclopentyl group have been shown to retain potent JAK2 inhibitory activity.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Thus, piperidine <b>2</b>, incorporating the propionitrile-substituted pyrazole, was prepared in a similar way by Suzuki reaction of addition of 2,4-dichloropyrrolopyrimidine and the boronic ester <b>27</b> (from acrylonitrile and 4-pyrazoleboronic pinacolate<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>) to give the nitrile <b>28</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Scheme S3</a>). A similar sequence of Buchwald–Hartwig amination of the boc-protected 2-chloropyrrolopyrimidine <b>29</b> followed by deprotection of <b>30</b> provided piperidine <b>2</b>. The piperidine <b>3</b>, bearing a butenyl-substituted pyrazole group, was prepared using the same methods used to prepare piperidine <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Scheme S4</a>).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Methyl 3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanoate (<b>8</b>)</h4><div class="NLM_p last">This compound was prepared according to the reported method.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To a solution of 3-cyclopentyl methacrylate (4.56 g, 29.58 mol, 1.0 eq) in anhydrous acetonitrile (100 mL), 4-bromopyrazole (4.77 g, 32.49 mol, 1.1 eq) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (6.63 mL, 44.37 mol, 1.5 eq) were added. The reaction mixture was stirred overnight at room temperature. The mixture was concentrated under a reduced pressure and the residue was dissolved in ethyl acetate (EtOAc, 500 mL), 1 N HCl was added to adjust the pH value to 3 or 4, and then washed with water (100 mL) and brine (100 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under a reduced pressure to obtain the title compound as a colorless oil (7.02 g, 80%). This compound was used in the next step without purification. HPLC 98% (<i>t<sub>R</sub></i> = 13.1 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (s, 1H), 7.51 (s, 1H), 4.39 (m, 1H), 3.50 (s, 1H), 2.97 (m, 2H), 2.24 (m, 1H), 1.74 (m, 1H), 1.59–1.34 (m, 4H), 1.26–1.05 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 301.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanoic Acid (<b>9</b>)</h4><div class="NLM_p last">This compound was prepared according to the reported method.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To a solution of <b>8</b> (7.02 g, 23.40 mol, 1.0 eq), in dioxane (140 mL), was added sodium hydroxide (2.81 g, 70.20 mol, 3.0 eq) in water (70 mL). The reaction mixture was stirred overnight at room temperature. The mixture was concentrated under a reduced pressure and water (100 mL) was added followed by 1 N HCl to adjust the pH to 3 or 4. The aqueous layer was extracted with EtOAc (3 × 150 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and filtered, and concentrated under a reduced pressure to obtain the title compound as a white solid (6.20 g, 95%). This compound was used in the next step without further purification. HPLC 99% (<i>t<sub>R</sub></i> = 12.3 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.21 (s, 1H), 8.02 (s, 1H), 7.51 (s, 1H), 4.37 (m, 1H), 2.86 (m, 2H), 2.23 (m, 1H), 1.75 (m, 1H), 1.60–1.35 (m, 4H), 1.26–1.06 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 287.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (4<i>R</i>)-4-Benzyl-3-((<i>3R</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanoyl)Oxazolidin-2-One (4<i>R,3R</i>)-<b>10</b></h4><div class="NLM_p last">To a solution of <b>9</b> (5.73 g, 20.0 mol, 1.0 eq) in tetrahydrofuran (172 mL), pivaloyl chloride (4.93 mL, 40.0 mol, 2.0 eq) and triethylamine (8.34 mL, 60.0 mol, 3.0 eq) were added at 0 °C. The reaction mixture was stirred for 1 h at room temperature. To the reaction mixture, lithium chloride (1.70 g, 40.0 mol, 2.0 eq) and oxazolidinone (3.58 g, 20.0 mol, 1.0 eq) were added, and then the mixture was stirred overnight at room temperature. The reaction mixture was diluted with water (100 mL), evaporated under a reduced pressure to remove tetrahydrofuran, and extracted with EtOAc (3 × 150 mL). The organic layer was evaporated under a reduced pressure and the residue was purified by SiO<sub>2</sub> chromatography using EtOAc/hexane (20%) as an eluent to give the title compound as a white solid (3.9 g, 42%, TLC: R<i><sub>f</sub></i> = 0.51 developed using EtOAc/hexane (2:3)). HPLC 97% (<i>t<sub>R</sub></i> = 13.40 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (d, <i>J</i> = 0.7 Hz, 1H), 7.61 (s, 1H), 7.27–7.21 (m, 3H), 6.94–6.91 (m, 2H), 4.63–4.52 (m, 3H), 4.32 (t, <i>J</i> = 8.7 Hz, 1H), 4.17 (dd, <i>J</i> = 9.0, 3.1 Hz, 1H), 3.79 (dd, <i>J</i> = 17.6, 10.6 Hz, 1H), 3.20 (dd, <i>J</i> = 17.6, 2.9 Hz, 1H), 2.83–2.74 (m, 2H), 2.37–2.30 (m, 1H), 1.79–1.74 (m, 1H), 1.60–1.50 (m, 3H), 1.47–1.39 (m, 1H), 1.29–1.12 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 468.2 (M + Na)<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (4<i>R</i>)-4-Benzyl-3-((<i>3S</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanoyl)Oxazolidin-2-One (<i>4R,</i>3<i>S</i>-<b>10</b>)</h4><div class="NLM_p last">(<i><b>4R,</b>3<b>S</b></i>)<b>-10</b> was purified using the procedure described for (<i>4R,3R</i>)<b>-10</b> to obtain the title product as a white solid (4.0 g, 43%, TLC: R<i><sub>f</sub></i> = 0.62 developed using EtOAc/hexane (2:3)). HPLC 98% (<i>t<sub>R</sub></i> = 13.60 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (d, <i>J</i> = 0.8 Hz, 1H), 7.52 (d, <i>J</i> = 0.6 Hz, 1H), 7.34–7.30 (m, 2H), 7.28–7.24 (m, 1H), 7.22–7.19 (m, 2H), 4.61–4.49 (m, 2H), 4.28 (t, <i>J</i> = 8.5 Hz, 1H), 4.15 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 3.53 (dd, <i>J</i> = 17.1, 10.4 Hz, 1H), 3.37 (dd, <i>J</i> = 17.1, 3.0 Hz, 1H), 2.97 (dd, <i>J</i> = 13.6, 3.2 Hz, 1H), 2.84 (dd, <i>J</i> = 13.5, 8.3 Hz, 1H), 2.34–3.31 (m, 1H), 1.82–1.73 (m, 1H), 1.64–1.50 (m, 3H), 1.47–1.41 (m, 1H), 1.36–1.12 (m, 1H); HPLC–MS (ESI+): <i>m/z</i> 446.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>S</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanamide (<b>11</b>)</h4><div class="NLM_p last">The amide <b>11</b> was synthesized using the same procedure described for <b>17</b> from (<i>4R,3S</i>)<b>-10</b> (7.6 mmol, 3.4 g) as a white solid (1.9 g, 87%). HPLC 97.2% (<i>t<sub>R</sub></i> = 11.4 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (s, 1H), 7.51 (s, 1H), 7.30 (s, 1H), 6.76 (s, 1H), 4.41 (td, <i>J</i> = 9.7, 4.1 Hz, 1H), 2.76 (dd, <i>J</i> = 15.3, 10.0 Hz, 1H), 2.57 (dd, <i>J</i> = 15.3, 4.0 Hz, 1H), 2.24 (h, <i>J</i> = 8.6 Hz, 1H), 1.79–1.70 (m, 1H), 1.59–1.35 (m, 4H), 1.24–1.06 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 286.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>S</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile (<b>12</b>)</h4><div class="NLM_p last">The nitrile <b>12</b> was synthesized using the same procedure described for <b>18</b> from amide <b>11</b> (6.6 mmol, 1.9 g) as a white solid (1.6 g, 94%). HPLC 97.2% (<i>t<sub>R</sub></i> = 12.5 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13 (d, <i>J</i> = 0.7 Hz, 1H), 7.63 (s, 1H), 4.38 (td, <i>J</i> = 9.4, 4.7 Hz, 1H), 3.15–3.05 (m, 2H), 2.36–2.26 (m, 1H), 1.80–1.69 (m, 2H), 1.62–1.37 (m, 4H), 1.30–1.19 (m, 2H), 1.08 (dq, <i>J</i> = 12.7, 8.3 Hz, 1H); HPLC–MS (ESI+): <i>m/z</i> 268.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>S</i>)-3-Cyclopentyl-3-(4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile (<b>13</b>)</h4><div class="NLM_p last">The boronic ester <b>13</b> was synthesized using the same procedure described for <b>13</b> from (<i>S</i>)-bromopyrazole <b>19</b> (1.1 mmol, 0.3 g) as a white solid (165 mg, 47%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.08 (s, 1H), 7.95 (s, 1H), 4.43 (td, <i>J</i> = 9.7, 4.3 Hz, 1H), 3.15–3.09 (m, 2H), 2.37–2.27 (m, 1H), 1.80–1.71 (m, 1H), 1.58–1.37 (m, 4H), 1.25 (s, 12H), 1.20–1.15 (m, 3H).</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>S</i>)-3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile [(<i>S</i>)-Ruxolitinib]</h4><div class="NLM_p last">(<i>S</i>)-Ruxolitinib was synthesized using the same procedure described for <b>14</b> from (<i>S</i>)-<b>13</b> (0.15 mmol, 49 mg) as a white solid (35 mg, 74%). HPLC 99.17% (<i>t<sub>R</sub></i> = 12.57 min, CH<sub>3</sub>OH 75% in 0.1% TFA water, 20 min); <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.10 (s, 1H), 8.79 (s, 1H), 8.67 (s, 1H), 8.37 (s, 1H), 7.59 (dd, <i>J</i> = 3.5, 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 3.6, 1.7 Hz, 1H), 4.54 (td, <i>J</i> = 9.8, 4.0 Hz, 1H), 3.26 (dd, <i>J</i> = 17.2, 9.8 Hz, 2H), 2.42 (dd, <i>J</i> = 17.1, 8.3 Hz, 1H), 1.86–1.78 (m, 1H), 1.65–1.40 (m, 4H), 1.35–1.17 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 307.2 (M+H)<sup>+</sup>. HRMS (ESI+) <i>m/z</i> calculated for C<sub>17</sub>H<sub>19</sub>N<sub>6</sub> (M + H)<sup>+</sup> 307.1666, found 307.1667.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (3<i>RS</i>)-3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile (<i>rac</i>-Ruxolitinib)</h4><div class="NLM_p last">To a solution of 4-bromo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (198 mg, 1.0 mmol, 1.0 eq), 3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile (378 mg, 1.2 mmol, 1.2 eq)[prepared from commercially available 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole and 3-cyclopentylprop-2-enenitrile according to a reported procedure],<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and Na<sub>2</sub>CO<sub>3</sub> (340 mg, 3.2 mmol, 3.2 eq) in dioxane (4 mL) and H<sub>2</sub>O (1 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (40 mg, 0.033 mmol, 0.033 eq). The pressure tube was purged with argon for 15 min, sealed, and then placed in a preheated oil bath at 120 °C. The mixture was stirred at this temperature for 12 h and then cooled to room temperature and partitioned between saturated NH<sub>4</sub>Cl (20 mL) and EtOAc (10 mL). The layers were separated, and the aqueous layer was extracted twice more with EtOAc (10 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated under a reduced pressure to give a yellow oil. Purification by flash chromatography (SiO<sub>2</sub>, 75% EtOAc in hexane) provided the title compound <i>rac</i>-ruxolitinib as a brown powder (0.224 g, 73%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.11 (s, 1H), 8.80 (d, <i>J</i> = 0.7 Hz, 1H), 8.68 (s, 1H), 8.37 (s, 1H), 7.60 (dd, <i>J</i> = 3.6, 2.4 Hz, 1H), 6.99 (dd, <i>J</i> = 3.6, 1.8 Hz, 1H), 4.54 (td, <i>J</i> = 9.8, 4.1 Hz, 1H), 3.20 (m, 3H), 2.43 (m, 1H), 1.82 (m, 1H), 1.61 (m, 3H), 1.46 (m, 1H), 1.39 (m, 2H), 1.18 (m, 1H). HPLC–MS (ESI+): <i>m/z</i> 307.4 [100% (M+H)<sup>+</sup>], HRMS (ESI+) <i>m/z</i> calculated for C<sub>17</sub>H<sub>19</sub>N<sub>6</sub> (M + H)<sup>+</sup> 307.1666, found 307.1662.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>S</i>)-3-(4-(2-Chloro-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile (<b>14</b>)</h4><div class="NLM_p last">The pyrrolopyrimidine <b>14</b> was synthesized using the same procedure described for <b>20</b> from (<i>S</i>)-boronic ester <b>13</b> (1.1 mmol, 0.3 g) as a white oil (151 mg, 41%). HPLC 78.0% (<i>t<sub>R</sub></i> = 11.99 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.32 (s, 1H), 8.84 (d, <i>J</i> = 0.7 Hz, 1H), 8.39 (s, 1H), 7.64 (dd, <i>J</i> = 3.6, 2.3 Hz, 1H), 7.05 (dd, <i>J</i> = 3.6, 1.8 Hz, 1H), 4.56 (td, <i>J</i> = 9.8, 4.1 Hz, 1H), 3.29–3.21 (m, 2H), 2.43 (q, <i>J</i> = 8.6 Hz, 1H), 1.82 (td, <i>J</i> = 11.9, 7.2 Hz, 1H), 1.66–1.41 (m, 4H), 1.33–1.23 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 341.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> tert-Butyl (<i>S</i>)-2-Chloro-4-(1-(2-Cyano-1-Cyclopentylethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>15</b>)</h4><div class="NLM_p last">The boc<b>-</b>protected pyrrolopyrimidine <b>15</b> was synthesized using the same procedure described for <b>21</b> from (<i>S</i>)-pyrrolopyrimidine <b>14</b> (0.27 mmol, 92 mg) as a white solid (70 mg, 68%). HPLC 95.8% (<i>t<sub>R</sub></i> = 13.6 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (d, <i>J</i> = 0.7 Hz, 1H), 8.44 (s, 1H), 7.92 (d, <i>J</i> = 4.1 Hz, 1H), 7.27 (d, <i>J</i> = 4.2 Hz, 1H), 4.56 (td, <i>J</i> = 9.7, 4.1 Hz, 1H), 3.29–3.21 (m, 2H), 2.43 (q, <i>J</i> = 8.6 Hz, 1H), 1.82 (td, <i>J</i> = 12.2, 7.4 Hz, 1H), 1.64 (s, 8H), 1.58–1.41 (m, 4H), 1.35–1.23 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 441.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> tert-Butyl (<i>S</i>)-2-((4-(1-(<i>tert</i>-Butoxycarbonyl)Piperidin-4-yl)Phenyl)Amino)-4-(1-(2-Cyano-1-Cyclopentylethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>16</b>)</h4><div class="NLM_p last">The <i>bis</i>-boc-protected pyrrolopyrimidine <b>16</b> was synthesized using the same procedure described for <b>22</b> from the (<i>S</i>)-pyrrolopyrimidine derivative <b>15</b> (0.09 mmol, 60 mg) as a yellow solid (47 mg, 76%). HPLC 97.0% (<i>t<sub>R</sub></i> = 15.04 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85 (s, 1H), 9.43 (s, 2H), 8.75 (d, <i>J</i> = 0.8 Hz, 1H), 8.33 (s, 1H), 7.92 (d, <i>J</i> = 8.6 Hz, 2H), 7.56 (d, <i>J</i> = 4.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.5 Hz, 2H), 7.04 (d, <i>J</i> = 4.2 Hz, 1H), 4.56 (td, <i>J</i> = 9.6, 4.4 Hz, 2H), 3.26–3.21 (m, 2H), 2.65–2.62 (m, 1H), 2.45–2.40 (m, 1H), 1.85–1.80 (m, 1H), 1.76 (d, <i>J</i> = 13.1 Hz, 2H), 1.66–1.52 (m, 15H), 1.43 (s, 9H), 1.36–1.26 (m, 5H); HPLC–MS (ESI+): <i>m/z</i> 681.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>S</i>)-3-Cyclopentyl-3-(4-(2-((4-(Piperidin-4-yl)Phenyl)Amino)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile <b>[(<i>S</i>)-1]</b></h4><div class="NLM_p last">The anilinopiperidine <b>(<i>S</i>)-1</b> was synthesized using the same procedure described for <b>(<i>R</i>)-1</b> from (<i>S</i>)-pyrrolopyrimidine <b>16</b> (0.06 mmol, 42 mg) as a yellow solid (24 mg, 83%). HPLC 97.6% (<i>t<sub>R</sub></i> = 7.76 min, CH<sub>3</sub>OH 50% and water 50% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.49 (s, 1H), 9.04 (s, 1H), 8.69 (s, 1H), 8.30 (s, 1H), 7.82–7.78 (m, 2H), 7.22 (dd, <i>J</i> = 3.7, 2.1 Hz, 1H), 7.15–7.11 (m, 2H), 6.79 (dd, <i>J</i> = 3.6, 1.6 Hz, 1H), 4.57 (td, <i>J</i> = 9.7, 4.2 Hz, 1H), 3.26–3.20 (m, 2H), 3.08 (d, <i>J</i> = 11.9 Hz, 2H), 2.68–2.61 (m, 2H), 1.87–1.80 (m, 1H), 1.73 (d, <i>J</i> = 12.6 Hz, 2H), 1.65–1.42 (m, 7H), 1.38–1.20 (m, 6H); HPLC–MS (ESI+): <i>m/z</i> 481.5 (M+H)<sup>+</sup>. HRMS (ESI+) <i>m/z</i> calculated for C<sub>28</sub>H<sub>33</sub>N<sub>8</sub> (M + H)<sup>+</sup> 481.2823, found 481.2830.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanamide (<b>17</b>)</h4><div class="NLM_p last">To a solution of (4<i>R,</i>3<i>R</i>)<b>-10</b> (3.0 g, 6.7 mol, 1.0 eq) in tetrahydrofuran (180 mL) was added ammonium hydroxide (30%, 120 mL). The reaction mixture was stirred for 2 days at room temperature. The mixture was diluted with methanol (250 mL), concentrated under a reduced pressure, and this process was repeated another two times. The residue obtained was purified by reverse-phase chromatography over a C-18 silica gel using methanol/dichloromethane (gradient elution 0 to 5%) as an eluent to give the title compound as a white solid (1.24 g, 64%). HPLC 95% (<i>t<sub>R</sub></i> = 11.44 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (d, <i>J</i> = 0.7 Hz, 1H), 7.51 (d, <i>J</i> = 0.7 Hz, 1H), 7.29 (s, 1H), 6.75 (s, 1H), 4.41 (td, <i>J</i> = 9.7, 4.0 Hz, 1H), 2.79–2.57 (m, 1H), 2.27–2.20 (m, 1H), 1.78–1.72 (m, 1H), 1.60–1.36 (m, 4H), 1.24–1.04 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 286.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-3-(4-Bromo-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile (<b>18</b>)</h4><div class="NLM_p last">This compound was prepared according to the reported method.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To a solution of <b>17</b> (1.24 g, 4.3 mol, 1.0 eq), in tetrahydrofuran (50 mL), was added phosphorus pentoxide (1.84 g, 13.0 mol, 3 eq) under argon. The reaction mixture was stirred for 2 h at 70 °C, diluted with EtOAc (200 mL), and quenched by adding saturated sodium bicarbonate (200 mL). The aqueous layer was back-extracted with EtOAc (2 × 100 mL). The organic phases were combined, washed with water, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The filtrate was concentrated under a reduced pressure and purified by SiO<sub>2</sub> chromatography using methanol/dichloromethane (5%) as an eluent to provide the title compound as a white solid (1.13 g, 98%). HPLC 100% (<i>t<sub>R</sub></i> = 12.56 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (d, <i>J</i> = 0.5 Hz, 1H), 7.63 (d, <i>J</i> = 0.5 Hz, 1H), 4.38 (td, <i>J</i> = 9.4, 4.7 Hz, 1H), 3.15–3.08 (m, 2H), 2.33–2.28 (m, 1H), 1.79–1.72 (m, 1H), 1.61–1.38 (m, 4H), 1.30–1.05 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 268.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-3-Cyclopentyl-3-(4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile (<b>19</b>)</h4><div class="NLM_p last">This compound was prepared according to the reported method.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To a 20 mL microwave vial, <b>18</b> (0.30 g, 1.12 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (0.30 g, 1.19 mmol, 1.1 eq), potassium acetate (329 mg, 3.36 mmol, 3.0 eq), and 1,4-dioxane (4.0 mL) were added. The resulting reaction mixture was degassed by bubbling argon for 5 min before being treated with tetrakis(triphenylphosphine)palladium(0) (65 mg, 0.06 mmol, 0.05 eq). The resulting reaction mixture was heated to 120 °C in a microwave reactor for 2 h. The reaction mixture was filtered through a celite bed, and the celite bed was washed with dichloromethane and the organic layer was diluted with water (10 mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic layers were concentrated under a reduced pressure, and the crude product was purified using SiO<sub>2</sub> chromatography (EtOAc 0–30% in hexane) to yield the title compound as a yellow oil (153 mg, 43%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (d, <i>J</i> = 0.7 Hz, 1H), 7.66 (d, <i>J</i> = 0.7 Hz, 1H), 4.43 (td, <i>J</i> = 9.6, 4.3 Hz, 1H), 3.19–3.05 (m, 2H), 2.33–2.31 (mz, 1H), 1.80–1.73 (m, 1H), 1.61–1.39 (m, 4H), 1.27 (s, 12H), 1.20–1.15 (m, 3H).</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-3-(4-(2-Chloro-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile (<b>20</b>)</h4><div class="NLM_p last">To a 50 mL round-bottom flask were added 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (87.0 mg, 0.46 mmol, 0.95 eq), <b>19</b> (153.0 mg, 0.49 mmol, 1 eq), sodium carbonate (191 mg, 1.38 mmol, 3 eq), water (0.5 mL), and 1,4-dioxane (2.0 mL), and the resulting reaction mixture was degassed by bubbling argon for 5 min before adding Pd(PPh<sub>3</sub>)<sub>4</sub> (17 mg, 0.01 mmol, 0.03 eq). The resulting reaction mixture was heated to 100 °C under argon overnight. The reaction mixture was gradually cooled down to ambient temperature and filtered through a celite bed. The celite bed was washed with dichloromethane (10 mL) and the organic layer was diluted with water (10 mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic layers were concentrated under a reduced pressure to remove solvents, and the crude product was purified by SiO<sub>2</sub> chromatography (EtOAc 0–60% in hexane) to yield the title compound as a yellow solid (94 mg, 68%). HPLC 74.7% (<i>t<sub>R</sub></i> = 11.93 min, CH<sub>3</sub>OH in 0.1% TFA water 5%∼95% in 20 min); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.32 (s, 1H), 8.84 (d, <i>J</i> = 0.8 Hz, 1H), 8.39 (s, 1H), 7.64 (d, <i>J</i> = 3.6, 1H), 7.05 (d, <i>J</i> = 3.6, 1H), 4.56 (td, <i>J</i> = 9.8, 4.0 Hz, 1H), 3.27–3.18 (m, 2H), 2.45–2.38 (m, 1H), 1.86–1.78 (m, 1H), 1.64–1.44 (m, 4H), 1.35–1.24 (m, 3H); HPLC–MS (ESI+): <i>m/z</i> 341.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (<i>R</i>)-2-Chloro-4-(1-(2-Cyano-1-Cyclopentylethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>21</b>)</h4><div class="NLM_p last">To a solution of pyrrolopyrimidine <b>20</b> (94.0 mg, 0.28 mmol, 1.0 eq), in dichloromethane (2.0 mL), <i>N</i>,<i>N</i>-diisopropylethylamine (0.058 mL, 0.33 mmol, 1.2 eq) was added and then di-<i>tert</i>-butyl dicarbonate (90.3 mg, 0.41 mmol, 1.5 eq) and 4-dimethylaminopyridine (7.0 mg, 0.06 mmol, 0.2 eq) were added. The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with water (10 mL) and extracted with dichloromethane (3 × 10 mL). The organic phase was evaporated under a reduced pressure and the residue was purified by SiO<sub>2</sub> chromatography using EtOAc/hexane (50%) as an eluent to give the title compound as a white solid (98 mg, 80%). HPLC 95.2% (<i>t<sub>R</sub></i> = 13.63 min, CH<sub>3</sub>OH in 0.1% TFA water 5%∼95% in 20 min); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (d, <i>J</i> = 0.8 Hz, 1H), 8.43 (s, 1H), 7.91 (d, <i>J</i> = 4.1 Hz, 1H), 7.26 (d, <i>J</i> = 4.2 Hz, 1H), 4.55 (td, <i>J</i> = 9.8, 4.0 Hz, 1H), 3.24–3.16 (m, 2H), 1.85–1.78 (m, 1H), 1.58–1.40 (m, 4H), 1.35–1.22 (m, 12H); HPLC–MS (ESI+): <i>m/z</i> 441.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>tert</i>-Butyl (<i>R</i>)-2-((4-(1-(<i>tert</i>-Butoxycarbonyl)Piperidin-4-yl)Phenyl)Amino)-4-(1-(2-Cyano-1-Cyclopentylethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>22</b>)</h4><div class="NLM_p last">A mixture of boc-pyrrolopyrimidine <b>21</b> (47.0 mg, 0.11 mmol, 1.0 eq), <i>tert</i>-butyl 4-(4-aminophenyl)piperidine-1-carboxylate (30.0 mg, 0.11 mmol, 1.0 eq), and potassium carbonate (30.0 mg, 2 mmol, 2.0 eq) in anhydrous <i>tert</i>-butyl alcohol (2 mL) was degassed by bubbling argon. To this mixture, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (10.0 mg, 0.021 mmol, 0.2 eq) and tris(dibenzylideneacetone)dipalladium (10.0 mg, 0.01 mmol, 0.1 eq) were added. The reaction was refluxed overnight and then allowed to cool to room temperature; water was added (10 mL) and the mixture was extracted with dichloromethane (3 × 10 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered, and the solvent was removed under a reduced pressure. The residue was purified by SiO<sub>2</sub> chromatography using EtOAc/hexane (50%) as an eluent to give the title compound as a yellow solid (54 mg, 89%). HPLC 97.1% (<i>t<sub>R</sub></i> = 15.13 min, CH<sub>3</sub>OH in 0.1% TFA water 5%∼95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 1H), 8.75 (d, <i>J</i> = 0.7 Hz, 1H), 8.33 (s, 1H), 7.93–7.90 (m, 2H), 7.56 (d, <i>J</i> = 4.2 Hz, 1H), 7.15 (d, <i>J</i> = 8.6 Hz, 2H), 7.04 (d, <i>J</i> = 4.2 Hz, 1H), 4.56 (td, <i>J</i> = 9.6, 4.3 Hz, 1H), 3.27–3.20 (m, 2H), 2.46–2.43 (m, 1H), 1.87–1.79 (m, 1H), 1.76 (d, <i>J</i> = 13.0 Hz, 2H), 1.66 (s, 9H), 1.57–1.45 (m, 6H), 1.43 (s, 9H), 1.37–1.16 (m, 8H); HPLC–MS (ESI+): <i>m/z</i> 681.5 (M + H)<sup>+</sup>.</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-3-Cyclopentyl-3-(4-(2-((4-(Piperidin-4-yl)Phenyl)Amino)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile [(<i>R</i>)-1)]</h4><div class="NLM_p last">The <i>bis</i>-boc-protected derivative <b>16</b> (54.0 mg, 0.08 mmol, 1.0 eq) was suspended in dichloromethane (2 mL) and TFA (0.12 mL, 1.59 mmol, 20.0 eq) was added. The mixture was stirred at room temperature for 2 h and concentrated under a reduced pressure. The residue was dissolved in chloroform and washed with 10% potassium carbonate (aq.). The aqueous layer was extracted with chloroform (3 × 10 mL) and the combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and filtered. The filtrate was concentrated under a reduced pressure, and the product was dried under vacuum to afford the title compound as a white solid (47 mg, 95%). HPLC 98.7% (<i>t<sub>R</sub></i> = 11.00 min, CH<sub>3</sub>OH in 0.1% TFA water 5–95% in 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.49 (s, 1H), 9.01 (s, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 7.80–7.76 (m, 2H), 7.21 (d, <i>J</i> = 3.6 Hz, 1H), 7.14–7.10 (m, 2H), 6.78 (d, <i>J</i> = 3.6 Hz, 1H), 4.56 (td, <i>J</i> = 9.6, 4.1 Hz, 1H), 3.22–3.17 (m, 2H), 3.02 (d, <i>J</i> = 11.9 Hz, 1H), 2.44–2.42 (m, 1H), 1.81–1.85 (m, 1H), 1.68 (d, <i>J</i> = 13.0 Hz, 2H), 1.61–1.44 (m, 6H), 1.36–1.22 (m, 8H); HPLC–MS (ESI+): <i>m/z</i> 681.5 (M+H)<sup>+</sup>. HRMS (ESI+) <i>m/z</i> calculated for C<sub>28</sub>H<sub>33</sub>N<sub>8</sub> (M+H)<sup>+</sup> 481.2823, found 481.2830.</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-(4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile (<b>27</b>)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></h4><div class="NLM_p last">Using the reported method,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> a 100 mL round-bottom flask was charged with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (5.0 g, 25.8 mmol, 1.0 eq), acrylonitrile (1.04 g, 52.0 mmol, 2.0 eq), DBU (1.97 g, 12.9 mmol, 0.5 eq), and acetonitrile (50 mL). The mixture was stirred at room temperature overnight. After cooling, the mixture was diluted with EtOAc, washed with water twice and brine once, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, the filtrate was concentrated under a reduced pressure to yield the nitrile <b>27</b> as a yellow oil (3.9 g, 62%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (d, <i>J</i> = 0.6 Hz, 1H), 7.65 (d, <i>J</i> = 0.7 Hz, 1H), 4.41 (t, <i>J</i> = 6.4 Hz, 2H), 3.07 (t, <i>J</i> = 6.4 Hz, 2H), 1.26 (s, 9H).</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(4-(2-Chloro-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile (<b>28</b>)</h4><div class="NLM_p last">To a 50 mL round-bottom flask were added 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (3.0 g, 12.0 mmol, 1.2 eq), 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile <b>27</b> (0.51 g, 10.0 mmol, 1.0 eq), sodium carbonate (3.4 g, 31.6 mmol, 3.16 eq), water (H<sub>2</sub>O, 13 mL), and 1,4-dioxane (53 mL), and the resulting reaction mixture was degassed by bubbling argon for 5 min before being treated with Pd(PPh<sub>3</sub>)<sub>4</sub> (384 mg, 0.333 mmol). The resulting reaction mixture was heated to 100 °C under argon overnight. The reaction mixture was gradually cooled to ambient temperature before being filtered through a celite bed. The celite bed was washed with dichloromethane before the filtrate and washes were combined. The two layers were separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were concentrated under a reduced pressure to remove solvents, and the residue was purified by column chromatography (EtOAc 0 to 50% in hexane) to yield the title compound <b>28</b> as a brown solid (1.8 g, 69%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.33 (s, 1H), 8.81 (d, <i>J</i> = 0.7 Hz, 1H), 8.37 (d, <i>J</i> = 0.7 Hz, 1H), 7.64 (dd, <i>J</i> = 3.6, 2.3 Hz, 1H), 7.03 (dd, <i>J</i> = 3.6, 1.7 Hz, 1H), 4.53 (t, <i>J</i> = 6.4 Hz, 2H), 3.19 (t, <i>J</i> = 6.4 Hz, 2H). HPLC–MS (ESI+): <i>m/z</i> 273.4 (M+1)<sup>+</sup>, 567.3 (2 M+Na)<sup>+</sup>.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>tert</i>-Butyl-2-Chloro-4-(1-(2-Cyanoethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>29</b>)</h4><div class="NLM_p last">To a solution of chloropyrrolopyrimidine <b>28</b> (850 mg, 3.12 mmol, 1.2 eq) in DCM (15 mL) were added (Boc)<sub>2</sub>O (1.0 g, 4.68 mmol, 1.5 eq), DIPEA (0.49 g, 3.75 mmol, 1.2 eq), and DMAP (76 mg, 0.624 mmol, 0.2 eq). The reaction mixture was stirred at room temperature for 12 h, quenched with water, and extracted with EtOAc (2 × 20 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to yield the title compound <b>29</b> as a brown solid (1.12 g, 96%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (d, <i>J</i> = 0.9 Hz, 1H), 8.40 (d, <i>J</i> = 0.7 Hz, 1H), 7.91 (d, <i>J</i> = 4.1 Hz, 1H), 7.25 (d, <i>J</i> = 4.2 Hz, 1H), 4.53 (t, <i>J</i> = 6.4 Hz, 2H), 3.19 (t, <i>J</i> = 6.4 Hz, 2H), 1.64 (s, 9H). HPLC–MS (ESI+): <i>m/z</i> 373.1 [60%, (M+H)<sup>+</sup>], 769.2 [100% (2M + Na)<sup>+</sup>].</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>tert</i>-Butyl-2-((4-(1-(<i>tert</i>-Butoxycarbonyl)Piperidin-4-yl)Phenyl)Amino)-4-(1-(2-Cyanoethyl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine-7-Carboxylate (<b>30</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl-2-chloro-4-(1-(2-cyanoethyl)-1<i>H</i>-pyrazol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-7-carboxylate (<b>29</b>) (0.37 g, 1.0 mmol, 1.2 eq), <i>tert</i>-butyl-4-(4-aminophenyl)piperidine-1-carboxylate (0.33 g, 1.2 mmol, 1.2 eq), and K<sub>2</sub>CO<sub>3</sub> (0.21 g, 1.5 mmol) in anhydrous <i><sup>t</sup></i>BuOH (10 mL) was degassed under argon. To this mixture were added XPhos (48 mg, 0.1 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (46 mg, 0.05 mmol) and the reaction mixture was heated for 6 h and then allowed to cool. Water (40 mL) was added and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with brine, dried, and filtered, and the solvent was removed under a reduced pressure. The residue was purified by flash chromatography (50% EtOAc/hexane) to yield the title compound <b>30</b> as a brown solid (0.40 g, 79%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 1H), 8.72 (d, <i>J</i> = 1.6 Hz, 1H), 8.31 (d, <i>J</i> = 1.5 Hz, 1H), 7.90 (d, <i>J</i> = 8.6 Hz, 1H), 7.55 (d, <i>J</i> = 4.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.7 Hz, 2H), 7.01 (d, <i>J</i> = 4.2 Hz, 1H), 4.53 (m, 2H), 4.02 (m, 2H), 3.16 (m, 2H), 2.80 (m, 2H), 2.6 (m, 1H), 1.75 (m, 2H), 1.65 (s, 9H), 1.47 (m, 2H), 1.42 (s, 9H). HPLC–MS (ESI+): <i>m/z</i> 613.1 [100%, (M + H)<sup>+</sup>].</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-(4-(2-((4-(Piperidin-4-yl)Phenyl)Amino)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-4-yl)-1<i>H</i>-Pyrazol-1-yl)Propanenitrile (2)</h4><div class="NLM_p last">To a solution of the <i>bis</i>-boc-protected pyrrolopyrimidine <b>30</b> (0.306 g, 0.5 mmol) in DCM (3 mL) was added TFA (3 mL) under an argon atmosphere, and the reaction mixture was stirred at room temperature for 4 h. After this time, there was no starting material present (as measured by HPLC), and the reaction was quenched with sat. NaHCO<sub>3</sub> solution and extracted with DCM (2 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness in vacuo to yield the title compound <b>2</b> as a brown solid (0.121 g, 81%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.49 (s, 1H), 9.06 (s, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.80 (d, <i>J</i> = 8.3 Hz, 2H), 7.22 (d, <i>J</i> = 3.6 Hz, 1H), 7.13 (d, <i>J</i> = 8.3 Hz, 2H), 6.77 (d, <i>J</i> = 3.6 Hz, 1H), 4.53 (t, <i>J</i> = 6.4 Hz, 2H), 3.13 (m, 4H), 2.69 (m, 2H), 2.60 (m, 1H), 1.77 (dd, <i>J</i> = 13.6, 3.4 Hz, 2H), 1.58 (m, 2H). HPLC–MS (ESI+): <i>m/z</i> 207.2 [100% (1/2 M+H)<sup>2+</sup>], 413.3 [40% (M + H)<sup>+</sup>]. <i>m/z</i> calculated for C<sub>23</sub>H<sub>25</sub>N<sub>8</sub> (M+H)<sup>+</sup> 413.2197, found 413.2191.</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(But-3-en-1-yl)-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1<i>H</i>-Pyrazole (<b>31</b>)</h4><div class="NLM_p last">A 100 mL round-bottom flask was charged with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (0.5 g, 2.58 mmol, 1.0 eq), 4-bromobutene (0.48 g, 3.6 mmol, 1.4 eq), cesium carbonate (1.67 g, 5.16 mmol, 2 eq), and acetonitrile (10 mL). The reaction mixture was stirred at 90 °C overnight. After cooling, the mixture was quenched with water (30 mL) and extracted with EtOAc (3 × 30 mL). The organic layers were combined, washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The solvent was evaporated under a reduced pressure to yield the title product as a yellow oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.78 (s, 1H), 7.67 (s, 1H), 5.78 (m, 1H), 5.09 (m, 2H), 4.20 (t, <i>J</i> = 7.5 Hz, 2H), 2.63 (m, 2H), 1.31 (s, 12H).</div></div><div id="sec4_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-(1-(But-3-en-1-yl)-1<i>H</i>-Pyrazol-4-yl)-2-Chloro-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine (<b>32</b>)</h4><div class="NLM_p last">A 50 mL round-bottom flask was charged with 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.3 g, 1.6 mmol, 1.0 eq), 1-(but-3-en-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole <b>31</b> (0.51 g, 2.08 mmol, 1.5 eq), sodium carbonate (0.33 g, 3.2 mmol, 2.0 eq), water (H<sub>2</sub>O, 5 mL), and 1,4-dioxane (15 mL). The reaction mixture was degassed by bubbling argon for 5 min before treating with Pd(PPh<sub>3</sub>)<sub>4</sub> (199 mg, 0.172 mmol, 0.107 eq). The mixture was heated to 100 °C under argon overnight. The reaction mixture was gradually cooled down to ambient temperature, quenched with water (20 mL), and extracted with EtOAc (3 × 30 mL). The organic layers were combined, washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The solvent was evaporated under a reduced pressure, and the residue was triturated with Et<sub>2</sub>O and hexane to give <b>32</b> as a yellow solid (0.32 g, 82%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d<sub>6</sub></i>) δ 12.28 (s, 1H), 8.69 (s, 1H), 8.28 (s, 1H), 7.60 (dd, <i>J</i> = 3.0, 1.5 Hz, 1H), 7.02 (d, <i>J</i> = 3.0 Hz, 1H), 5.84 (m, 1H), 5.08 (m, 2H), 4.31 (t, <i>J</i> = 7.5 Hz, 2H), 2.64 (m, 2H). HPLC–MS (ESI+): <i>m/z</i> 274.2 (M+1)<sup>+</sup>, 569.2 (2 M + Na)<sup>+</sup>.</div></div><div id="sec4_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-(1-(But-3-en-1-yl)-1<i>H</i>-Pyrazol-4-yl)-2-Chloro-7-Tosyl-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidine (<b>33</b>)</h4><div class="NLM_p last">To a solution of 4-(1-(but-3-en-1-yl)-1<i>H</i>-pyrazol-4-yl)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>32</b> (1.0 g, 5.32 mmol, 1.0 eq), <i>p</i>-toluenesulfonyl chloride (1.1 g, 5.85 mmol, 1.1 eq), and tetra-butylammonium hydrogen sulfate (0.090 g, 0.27 mmol, 0.05 eq) in dichloromethane (20 mL) was added NaOH (50% aq, 0.2 mL). The reaction mixture was stirred at room temperature for 30 min. After completion of the reaction (as indicated by TLC), the reaction mixture was diluted with H<sub>2</sub>O (20 mL). The organic layer was separated, washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The organic layer was evaporated under a reduced pressure to obtain a light yellow solid, which was purified by SiO<sub>2</sub> chromatography using hexane/EtOAc (5:1) as an eluent to give the title product (1.3 g, 85%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 8.29 (s, 1H), 8.04 (d, <i>J</i> = 4.5 Hz, 1H), 8.03 (d, <i>J</i> = 8.5 Hz, 2H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.37 (d, <i>J</i> = 4.5 Hz, 1H), 5.81 (m, 1H), 5.05 (m, 2H), 4.29 (t, <i>J</i> = 7.5 Hz, 2H), 2.61 (m, 2H). 2.37 (s, 3H). HPLC–MS (ESI+): <i>m/z</i> 428.1 (M+1)<sup>+</sup>, 877.1 (2M + Na)<sup>+</sup>.</div></div><div id="sec4_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>tert</i>-Butyl 4-(4-((4-(1-(But-3-en-1-yl)-1<i>H</i>-Pyrazol-4-yl)-7-Tosyl-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-2-yl)Amino)Phenyl)Piperidine-1-Carboxylate (<b>34</b>)</h4><div class="NLM_p last">A mixture of 4-(1-(but-3-en-1-yl)-1H-pyrazol-4-yl)-2-chloro-7-tosyl-7H-pyrrolo[2,3-<i>d</i>]pyrimidine <b>33</b> (300 mg, 0.7 mmol, 1.0 eq), <i>tert</i>-butyl 4-(4-aminophenyl)piperidine-1-carboxylate (200 mg, 0.74 mmol, 1.06 eq), and K<sub>2</sub>CO<sub>3</sub> (200 mg, 1.4 mmol, 2.0 eq) in anhydrous <i><sup>t</sup></i>BuOH (15 mL) was degassed by bubbling argon for 5 min. XPhos (33 mg, 0.07 mmol, 0.1 eq) and Pd<sub>2</sub>(dba)<sub>3</sub> (32 mg, 0.035 mmol, 0.05 eq) were added and the mixture was refluxed overnight. The mixture was allowed to cool to room temperature and quenched with water (40 mL). The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered, and the solvent was removed under a reduced pressure. The residue was purified by SiO<sub>2</sub> chromatography (0 to 60% EtOAc in hexane) to afford the title compound as a yellow solid (330 mg, 85%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.52 (s, 1H), 8.60 (s, 1H), 8.19 (s, 1H), 8.02 (d, <i>J</i> = 8.0 Hz, 2H), 7.87 (d, <i>J</i> = 8.0 Hz, 2H), 7.70 (d, <i>J</i> = 4.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 2H), 7.24 (d, <i>J</i> = 8.0 Hz, 2H), 5.79 (m, 1H), 5.07 (m, 2H), 4.30 (t, <i>J</i> = 7.5 Hz, 2H), 4.09 (br s, 2H), 2.82 (br s, 2H), 2.69–2.58 (m, 4H), 2.32 (s, 3H), 1.80 (m, 2H), 1.53 (m, 2H), 1.48 (s, 9H). HPLC–MS (ESI+): <i>m/z</i> 668.3 (M + 1)<sup>+</sup>.</div></div><div id="sec4_3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl 4-(4-((4-(1-(but-3-en-1-yl)-1<i>H</i>-Pyrazol-4-yl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-2-yl)Amino)Phenyl)Piperidine-1-Carboxylate (<b>35</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(4-((4-(1-(but-3-en-1-yl)-1<i>H</i>-pyrazol-4-yl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate <b>34</b> (165 mg, 0.29 mmol, 1.0 eq) in MeOH (5 mL) and H<sub>2</sub>O (3 mL) was added K<sub>2</sub>CO<sub>3</sub> (165 mg, 1.20 mmol, 4.0 eq) and the mixture was refluxed for 3 h. The mixture was diluted with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered, and the solvent was removed under a reduced pressure to give a yellow residue. The residue was purified by SiO<sub>2</sub> flash chromatography (0 to 70% EtOAc in hexane) to give the title compound (105 mg, 87%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 9.03 (s, 1H), 8.55 (s, 1H), 8.20 (s, 1H), 7.81 (d, <i>J</i> = 9.0 Hz, 2H), 7.19 (m, 1H), 7.14 (d, <i>J</i> = 9.0 Hz, 2H), 6.76 (m, 1H), 5.86 (m, 1H), 5.10 (m, 2H), 4.32 (t, <i>J</i> = 7.0 Hz, 2H), 4.10 (br s, 2H), 2.79 (br s, 2H), 2.65–2.58 (m, 3H), 1.76 (m, 2H), 1.49 (m, 2H), 1.42 (s, 9H). HPLC–MS (ESI+): <i>m/z</i> 514.4 (M + 1)<sup>+</sup>.</div></div><div id="sec4_3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(1-(But-3-en-1-yl)-1<i>H</i>-Pyrazol-4-yl)-<i>N</i>-(4-(Piperidin-4-yl)Phenyl)-7<i>H</i>-Pyrrolo[2,3-<i>d</i>]Pyrimidin-2-Amine (<b>3</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl-4-(4-((4-(1-(but-3-en-1-yl)-1<i>H</i>-pyrazol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)piperidine-1-carboxylate <b>35</b> (0.22 g, 0.43 mmol, 1.0 eq) was suspended in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) and TFA (0.65 mL, 8.5 mmol, 20 eq) was added. The mixture was stirred at room temperature for 2 h and concentrated under a reduced pressure. The residue was dissolved in CHCl<sub>3</sub> (20 mL) and washed with 10% K<sub>2</sub>CO<sub>3</sub> (aq). The aqueous layer was extracted with CHCl<sub>3</sub> (3 × 20 mL). The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The filtrate was concentrated under a reduced pressure, and the residue was dried under vacuum to afford the title compound as an off-white solid (0.13 g, 75%). HPLC 99.8% (<i>t<sub>R</sub></i> = 8.90 min, CH<sub>3</sub>OH 45% in H<sub>2</sub>O (0.1% TFA), 1 mL/min, 20 min); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 9.00 (s, 1H), 8.55 (s, 1H), 8.20 (s, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 2H), 7.19 (d, <i>J</i> = 4 Hz, 1H), 7.12 (d, <i>J</i> = 7.5 Hz, 2H), 6.76 (d, <i>J</i> = 4 Hz, 1H), 5.86 (m, 1H), 5.10 (m, 2H), 4.32 (t, <i>J</i> = 7.0 Hz, 2H), 3.02 (br d, <i>J</i> = 12.0 Hz, 2H), 2.65 (q, <i>J</i> = 7 Hz, 2H), 2.59 (t, <i>J</i> = 12.5 Hz, 2H), 1.68 (d, <i>J</i> = 12.0 Hz, 2H), 1.53 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.4, 154.2, 151.3, 140.0, 139.3, 139.1, 135.3, 131.3, 126.9, 123.6, 121.2, 118.7, 117.7, 107.6, 100.5, 51.3, 47.2, 42.4, 35.0, 34.3; HPLC–MS (ESI+): <i>m/z</i> 414.3 (M + 1)<sup>+</sup>; HRMS (ESI+) <i>m/z</i> calculated for C<sub>24</sub>H<sub>28</sub>N<sub>7</sub> (M + H)<sup>+</sup> 414.2401, found 414.2402.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Dianilinopyrimidine Inhibitors of JAK2</h3><div class="NLM_p"><i>N</i>-(2-Fluoro-5-((2-((3-fluoro-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2-methylpropane-2-sulfonamide (<b>4</b>)</div><div class="NLM_p">This was prepared according the method reported.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p"><i>N</i>-(5-((2-((3,5-Difluoro-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)-2-fluorophenyl)-2-methylpropane-2-sulfonamide (<b>5</b>)</div><div class="NLM_p">This was prepared according the method reported.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">4-((4-((4-Chloro-3-((1,1-dimethylethyl)sulfonamido)phenyl)amino)-5-methylpyrimidin-2-yl)amino)-2-fluoro-<i>N</i>-(1-methylpiperidin-4-yl)benzamide (<b>6</b>)</div><div class="NLM_p">This was prepared according the method reported.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p"><i>N</i><sup>4</sup>-(1-(<i>Tert</i>-Butylsulfonyl)indolin-6-yl)-<i>N</i><sup>2</sup>-(3-fluoro-4-(1-methylpiperidin-4-yl)phenyl)-5-methylpyrimidine-2,4-diamine (<b>7</b>)</div><div class="NLM_p">This was prepared according the method reported.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Cloning and Expression of JAK2 KD</h4><div class="NLM_p last">The DNA of human JAK2 KD (JH1), encoding amino acids 840–1132, was synthesized and cloned into pcDNA 3.3 (GeneArt). The construct was expressed using a CMV promoter and contained a His<sub>8</sub><i>N</i>-terminal affinity tag followed by a TEV cleavage site. Expi293F cells (Invitrogen) were grown, maintained, and treated in a shaking culture at 37 °C with 8% CO<sub>2</sub> in Expi293 medium (Invitrogen). Recombinant JAK2 was expressed in Expi293F cells using Transporter 5 transfection reagent as described by the manufacturer (Polysciences). One hour after adding the plasmid/transfection complex, varying concentrations of the JAK2 inhibitor or the transcription enhancer were added as indicated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The transfection proceeded for 24 h before harvest. Cells used for the preparation of crystallization-grade JAK2 were incubated with 1 μM ruxolitinib and 4 mM butyric acid for 23 h.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Purification of JAK2 KD</h4><div class="NLM_p last">Purification of JAK2 KD was performed at 4 °C. Expi293F cells were centrifuged at 1000 × g for 30 min at 4 °C. Cells were resuspended in lysis buffer (50 mM HEPES pH 7.5, 250 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 5 mM MgCl<sub>2</sub>, 0.1 mM ATP, 10 mM imidazole, 1 mM PMSF, and 0.5% Triton X-100). The cells were sonicated at 40% power for 2 min on ice and then centrifuged at 40,000 × g for 1 h at 4 °C to clarify the lysate. The soluble lysate was loaded onto two 5 mL HisTrap FF columns in tandem (GE Healthcare). The columns were washed with 10 mM imidazole, 40 mM imidazole, 100 mM imidazole, and 200 mM imidazole before applying a gradient up to 600 mM imidazole. The protein was concentrated to 10 mL using a 10,000 MWCO filter and loaded onto an S75 gel filtration column (GE Healthcare) that was pre-equilibrated with 40 mM bicine pH 8.6, 100 mM NaCl, and 10% glycerol. The single JAK2 peak, as determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis (>99% purity), was collected, concentrated to 8.1 mg/mL using a 3000 MWCO spin concentrator, flash-frozen in liquid N<sub>2</sub>, and stored at −80 °C.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Cellular Thermal Shift Assay</h4><div class="NLM_p last">CETSA was used to compare the melting curves from ligand-based thermal stabilization of JAK2 KD. Expi293F cells were transfected with His-JAK2 KD from pcDNA 3.3 as described above. Ruxolitinib (20 μM), or the equivalent amount of DMSO, was added to the cells and incubated for 1 h at 37 °C. After 1 h, the cells were centrifuged at 300 × g for 3 min at room temperature. The cells were washed with 15 mL of PBS and centrifuged again at 300 × g for 3 min. The cells were resuspended in 1 mL of PBS and approximately 3 × 10<sup>6</sup> cells were added to PCR tubes that were incubated at 40, 43, 46, 49, 52, 55, 58, 61, 64, or 67 °C for 3 min. The tubes were then flash-frozen in liquid N<sub>2</sub> and thawed twice at 25 °C. The cells were vortexed at 20,000 × g for 20 min at 4 °C. The soluble lysate was transferred to a new tube, a 5 × SDS-PAGE loading buffer was added, and 13 μL (equivalent of 3.3 × 10<sup>5</sup> cells) was added to an SDS-PAGE gel. The gel was transferred using the eBlot transfer system (GenScript), blocked with 5% BSA in TBS-T, and blotted for anti-His-HRP, anti-actin, or anti-GAPDH-HRP for 2 h at room temperature. The anti-actin blot was washed and then incubated with an anti-mouse-HRP-conjugated secondary antibody at 1:2000 for 1 h at room temperature. The blots were incubated with SignalFire ECL (Cell Signaling, 6883) and imaged using a GE Healthcare AmerSham Imager 600.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Isothermal Dose Response</h4><div class="NLM_p last">ITDR measures protein stabilization as a function of increasing inhibitor concentration. After performing the CETSA assay described above, the data were graphed and a temperature at the IC<sub>50</sub> value (47 °C) was used for the ITDR experiment. Expi293F cells were transfected with His-JAK2 KD. The cells were centrifuged at 300 × g for 3 min at room temperature. Cells were resuspended at a density of 4 × 10<sup>7</sup> cells/mL. Serial dilutions were performed yielding threefold dilutions ranging from 10 nM to 20 μM inhibitor with constant amounts of DMSO. Cells (approximately 1.2 × 10<sup>6</sup> cells) were added to the compounds and were incubated for 30 min at 37 °C with shaking every 10 min. The tubes were heated at 47 °C for 3 min. The cells were then vitrified and thawed twice at 25 °C before being vortexed at 20,000 × g for 20 min at 4 °C. The soluble supernatant was transferred to a new tube, mixed with a 5 × SDS-loading dye, and resolved on SDS-PAGE. The western blot transfer and incubation are the same as described above. Data were normalized to 0% and 100%.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Cell Viability Assays</h4><div class="NLM_p last">UKE-1 cells were cultured in RPMI-1640 with 10% FBS at 37 °C with 5% CO<sub>2</sub>. Suspension cells were seeded at 20,000 cells per well. Cells were incubated with increasing concentrations of compound ranging from 1 nM to 10 μM (as denoted in the figure legends) in the presence of a vehicle (0.2% DMSO) with six replicates per concentration for 72 h at 37 °C. After drug treatment, 15 μL of CellTiter Blue (Promega) was added to each well, mixed for 1 min using an orbital shaker, and incubated at 37 °C for 3 h. Fluorescence was measured using a Wallac EnVision 2130 plate reader (PerkinElmer). Excitation and emission filters of 570 and 615 nm were used, respectively. The cell viability data were analyzed using GraphPad Prism6.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Protein Crystallography</h4><div class="NLM_p last">Purified His-JAK2 KD at 8.1 mg/mL was incubated with 1 mM ruxolitinib and then added to 0.2 M NaCl, 0.1 M Bis–Tris pH 5.5, and 25% PEG 3350 in a 1:1 v/v ratio on a hanging drop coverslip with the crystallization solution at 293 K. Rodlike crystals were formed within 10 h and grew to a maximum size over 5 days. Ligand exchange was performed by moving JAK2–ruxolitinib crystals into the crystallization solution containing 1 mM inhibitor of interest for 3 days. The crystals were preserved in a cryoprotectant containing the crystallization solution and 30% glycerol. All data were collected on the 23-ID beamline, GM/CA at the Advanced Photon Source (Argonne, IL). Data were processed and scaled with XDS. Molecular replacement (using PDB 2XA4 as the search model) and refinements were carried out using PHENIX, and model building was performed using Coot. Figures were prepared using PyMOL (Schrödinger, LLC). All structures were validated and deposited in the PDB with accession codes listed in Supplementary <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Tables S1-S2</a>.</div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">PDB ID Codes</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">6VGL (JAK2/ruxolitinib), 6VSN (JAK2/S-ruxolitinib), 6VNK (JAK2/rac-ruxolitinib), 6VN8 (JAK2/baricitinib), 6VNC (JAK2/R-<b>1</b>), 6VNB (JAK2/S-<b>1</b>), 6VS3 (JAK2/rac-<b>1</b>), 6VNJ (JAK2/<b>2</b>), 6VNM (JAK2/<b>3</b>), 6VNE (JAK2/fedratinib), 6VNG (JAK2/<b>4</b>), 6VNH (JAK2/<b>5</b>), 6VNL (JAK2/<b>6</b>), and 6VNF (JAK2/<b>7</b>). Authors will release the atomic coordinates and structure factors upon article publication.</div><div class="NLM_p last">The authors declare no competing financial interest.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01952" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01952?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01952</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Supplementary figures, schematics and tables (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_001.csv">jm0c01952_si_001.csv (1.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf">jm0c01952_si_002.pdf (2.49 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01952" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernst Schönbrunn</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3589-3510" title="Orcid link">http://orcid.org/0000-0002-3589-3510</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e287908c9196cc91818a8d8c8090978c8ca28f8d84848b9696cc8d9085"><span class="__cf_email__" data-cfemail="a4c1d6cad7d08ad7c7cccbcac6d6d1cacae4c9cbc2c2cdd0d08acbd6c3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan R. Davis</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baoli Li</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sang Y. Yun</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Chan</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pradeep Nareddy</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Gunawan</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Ayaz</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harshani R. Lawrence</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Core, Moffitt Cancer Center, Tampa, Florida 33612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9263-7775" title="Orcid link">http://orcid.org/0000-0002-9263-7775</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary W. Reuther</span> - <span class="hlFld-Affiliation affiliation">Molecular
Oncology Department, Moffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas J. Lawrence</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery DepartmentMoffitt Cancer Center, Tampa, Florida 33612, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15066" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15066" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the GM/CA station at the Argonne National Laboratory for assistance with synchrotron data collection (National Cancer Institute grant Y1-CO-1020, National Institute of General Medical Sciences grant Y1-GM-1104, and U.S. Department of Energy contract W-31-109-ENG-38). We thank the Moffitt Chemical Biology Core for use of the crystallization and crystallography facility, and NMR and mass spectrometry instruments (National Cancer Institute grant P30-CA076292). H.R.L. acknowledges support by the National Cancer Institute grant R50CA211447. This work was supported by the Leukemia & Lymphoma Society (Screen-to-lead grant 8012-18) and the Florida Department of Health (Bankhead–Coley grant 20B10).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">MPN</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasms</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">STATs</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription proteins</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span> <span> </span><span class="NLM_article-title">Cancer genome landscapes</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1126/science.1235122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1126%2Fscience.1235122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23539594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=1546-1558&author=B.+Vogelsteinauthor=N.+Papadopoulosauthor=V.+E.+Velculescuauthor=S.+Zhouauthor=L.+A.+Diazauthor=K.+W.+Kinzler&title=Cancer+genome+landscapes&doi=10.1126%2Fscience.1235122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer genome landscapes</span></div><div class="casAuthors">Vogelstein, Bert; Papadopoulos, Nickolas; Velculescu, Victor E.; Zhou, Shibin; Diaz, Luis A., Jr.; Kinzler, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6127</span>),
    <span class="NLM_cas:pages">1546-1558</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer.  For most cancer types, this landscape consists of a small no. of "mountains" (genes altered in a high percentage of tumors) and a much larger no. of "hills" (genes altered infrequently).  To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or "drive" tumorigenesis.  A typical tumor contains two to eight of these "driver gene" mutations; the remaining mutations are passengers that confer no selective growth advantage.  Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance.  A better understanding of these pathways is one of the most pressing needs in basic cancer research.  Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXBcf6dWj0bVg90H21EOLACvtfcHk0liLnPrQB4xTtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOhsb0%253D&md5=da190782f210873557cbf15441540ee7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1235122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1235122%26sid%3Dliteratum%253Aachs%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DCancer%2520genome%2520landscapes%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D1546%26epage%3D1558%26doi%3D10.1126%2Fscience.1235122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into regulation of JAK2 tyrosine kinase</span>. <i>Front. Endocrinol. (Lausanne)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.3389%2Ffendo.2017.00361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29379470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvlt1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=361&author=S.+R.+Hubbard&title=Mechanistic+insights+into+regulation+of+JAK2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase</span></div><div class="casAuthors">Hubbard Stevan R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">361</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">JAK2 is a member of the Janus kinase (JAKs) family of non-receptor protein tyrosine kinases, which includes JAK1-3 and TYK2.  JAKs serve as the cytoplasmic signaling components of cytokine receptors and are activated through cytokine-mediated trans-phosphorylation, which leads to receptor phosphorylation and recruitment and phosphorylation of signal transducer and activator of transcription (STAT) proteins.  JAKs are unique among tyrosine kinases in that they possess a pseudokinase domain, which is just upstream of the C-terminal tyrosine kinase domain.  A wealth of biochemical and clinical data have established that the pseudokinase domain of JAKs is crucial for maintaining a low basal (absence of cytokine) level of tyrosine kinase activity.  In particular, gain-of-function mutations in the JAK genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.  Recent structural and biochemical studies have begun to decipher the molecular mechanisms that maintain the basal, low-activity state of JAKs and that, via mutation, lead to constitutive activity and disease.  This review will examine these mechanisms and describe how this knowledge could potentially inform drug development efforts aimed at obtaining a mutant (V617F)-selective inhibitor of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRk0uCTffMr3-2qxNLjzXe8fW6udTcc2eamMmJ2ESP_N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvlt1GgsQ%253D%253D&md5=1c051c523530ee188e915763c7651679</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2017.00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2017.00361%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DMechanistic%2520insights%2520into%2520regulation%2520of%2520JAK2%2520tyrosine%2520kinase%26jtitle%3DFront.%2520Endocrinol.%2520%2528Lausanne%2529%26date%3D2017%26volume%3D8%26spage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesarwani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kincaid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evelyn, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesiada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span> <span> </span><span class="NLM_article-title">Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">14538</span> <span class="refDoi"> DOI: 10.1038/srep14538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fsrep14538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=26419724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=M.+Kesarwaniauthor=E.+Huberauthor=Z.+Kincaidauthor=C.+R.+Evelynauthor=J.+Biesiadaauthor=M.+Ranceauthor=M.+B.+Thapaauthor=N.+P.+Shahauthor=J.+Mellerauthor=Y.+Zhengauthor=M.+Azam&title=Targeting+substrate-site+in+Jak2+kinase+prevents+emergence+of+genetic+resistance&doi=10.1038%2Fsrep14538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance</span></div><div class="casAuthors">Kesarwani, Meenu; Huber, Erika; Kincaid, Zachary; Evelyn, Chris R.; Biesiada, Jacek; Rance, Mark; Thapa, Mahendra B.; Shah, Neil P.; Meller, Jarek; Zheng, Yi; Azam, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14538</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Emergence of genetic resistance against kinase inhibitors poses a great challenge for durable therapeutic response.  Here, we report a novel mechanism of JAK2 kinase inhibition by fedratinib (TG101348) that prevents emergence of genetic resistance.  Using in vitro drug screening, we identified 211 amino-acid substitutions conferring resistance to ruxolitinib (INCB018424) and cross-resistance to the JAK2 inhibitors AZD1480, CYT-387 and lestaurtinib.  In contrast, these resistant variants were fully sensitive to fedratinib.  Structural modeling, coupled with mutagenesis and biochem. studies, revealed dual binding sites for fedratinib.  In vitro binding assays using purified proteins showed strong affinity for the substrate-binding site (Kd = 20 nM) while affinity for the ATP site was poor (Kd = ∼8 μM).  Our studies demonstrate that mutations affecting the substrate-binding pocket encode a catalytically incompetent kinase, thereby preventing emergence of resistant variants.  Most importantly, our data suggest that in order to develop resistance-free kinase inhibitors, the next-generation drug design should target the substrate-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRRslm0pE7PrVg90H21EOLACvtfcHk0lhgrVxDusQoCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ks7rE&md5=f4cab9a5e41db436796b0e0aedd4d105</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsrep14538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep14538%26sid%3Dliteratum%253Aachs%26aulast%3DKesarwani%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DE.%26aulast%3DKincaid%26aufirst%3DZ.%26aulast%3DEvelyn%26aufirst%3DC.%2BR.%26aulast%3DBiesiada%26aufirst%3DJ.%26aulast%3DRance%26aufirst%3DM.%26aulast%3DThapa%26aufirst%3DM.%2BB.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DMeller%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26atitle%3DTargeting%2520substrate-site%2520in%2520Jak2%2520kinase%2520prevents%2520emergence%2520of%2520genetic%2520resistance%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep14538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+activation+as+a+mechanism+of+persistence+to+JAK2+inhibitor+therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0ljmlCugfO95dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520activation%2520as%2520a%2520mechanism%2520of%2520persistence%2520to%2520JAK2%2520inhibitor%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorantla, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib mediated paradox JAK2 hyperphosphorylation is due to the protection of activation loop phosphotyrosines from phosphatases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>, <span class="NLM_elocation-id">2847</span> <span class="refDoi"> DOI: 10.1182/blood.V122.21.2847.2847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood.V122.21.2847.2847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&author=S.+P.+Gorantlaauthor=K.+S.+Babuauthor=A.+L.+Illertauthor=N.+von+Bubnoffauthor=C.+Peschelauthor=J.+Duyster&title=Ruxolitinib+mediated+paradox+JAK2+hyperphosphorylation+is+due+to+the+protection+of+activation+loop+phosphotyrosines+from+phosphatases&doi=10.1182%2Fblood.V122.21.2847.2847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood.V122.21.2847.2847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V122.21.2847.2847%26sid%3Dliteratum%253Aachs%26aulast%3DGorantla%26aufirst%3DS.%2BP.%26aulast%3DBabu%26aufirst%3DK.%2BS.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520mediated%2520paradox%2520JAK2%2520hyperphosphorylation%2520is%2520due%2520to%2520the%2520protection%2520of%2520activation%2520loop%2520phosphotyrosines%2520from%2520phosphatases%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26doi%3D10.1182%2Fblood.V122.21.2847.2847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tvorogov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liau, N. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dottore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hercus, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stomski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tergaonkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, A. F.</span></span> <span> </span><span class="NLM_article-title">Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">eaat3834</span> <span class="refDoi"> DOI: 10.1126/sciadv.aat3834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1126%2Fsciadv.aat3834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=30498775" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&author=D.+Tvorogovauthor=D.+Thomasauthor=N.+P.+D.+Liauauthor=M.+Dottoreauthor=E.+F.+Barryauthor=M.+Lathiauthor=W.+L.+Kanauthor=T.+R.+Hercusauthor=F.+Stomskiauthor=T.+P.+Hughesauthor=V.+Tergaonkarauthor=M.+W.+Parkerauthor=D.+M.+Rossauthor=R.+Majetiauthor=J.+J.+Babonauthor=A.+F.+Lopez&title=Accumulation+of+JAK+activation+loop+phosphorylation+is+linked+to+type+I+JAK+inhibitor+withdrawal+syndrome+in+myelofibrosis&doi=10.1126%2Fsciadv.aat3834"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat3834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat3834%26sid%3Dliteratum%253Aachs%26aulast%3DTvorogov%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DLiau%26aufirst%3DN.%2BP.%2BD.%26aulast%3DDottore%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DE.%2BF.%26aulast%3DLathi%26aufirst%3DM.%26aulast%3DKan%26aufirst%3DW.%2BL.%26aulast%3DHercus%26aufirst%3DT.%2BR.%26aulast%3DStomski%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DTergaonkar%26aufirst%3DV.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26aulast%3DMajeti%26aufirst%3DR.%26aulast%3DBabon%26aufirst%3DJ.%2BJ.%26aulast%3DLopez%26aufirst%3DA.%2BF.%26atitle%3DAccumulation%2520of%2520JAK%2520activation%2520loop%2520phosphorylation%2520is%2520linked%2520to%2520type%2520I%2520JAK%2520inhibitor%2520withdrawal%2520syndrome%2520in%2520myelofibrosis%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26doi%3D10.1126%2Fsciadv.aat3834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+structures+of+the+JAK2+pseudokinase+domain+and+the+pathogenic+mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies α-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0lgE1gCr7h0nJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structures%2520of%2520the%2520JAK2%2520pseudokinase%2520domain%2520and%2520the%2520pathogenic%2520mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms</span>. <i>Hematol. Oncol. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.hoc.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=28673392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=627-642&author=S.+C.+Meyer&title=Mechanisms+of+resistance+to+JAK2+inhibitors+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.hoc.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms</span></div><div class="casAuthors">Meyer Sara C</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-642</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells.  JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone.  Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and functional, have been identified.  Resistance mutations have not been reported in MPN patients suggesting incomplete target inhibition.  Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors.  Additional combined therapy approaches are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsWLFM_lbR1VmfW6udTcc2eZ2FTdt5wxDJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D&md5=195db657c3d8a32ffc83932047d37595</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520JAK2%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D31%26spage%3D627%26epage%3D642%26doi%3D10.1016%2Fj.hoc.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousoik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montazeri Aliabadi, H.</span></span> <span> </span><span class="NLM_article-title">Do we know jack about JAK? A closer look at JAK/STAT signaling pathway</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">287</span> <span class="refDoi"> DOI: 10.3389/fonc.2018.00287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.3389%2Ffonc.2018.00287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=30109213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ot1Crtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=E.+Bousoikauthor=H.+Montazeri+Aliabadi&title=Do+we+know+jack+about+JAK%3F+A+closer+look+at+JAK%2FSTAT+signaling+pathway&doi=10.3389%2Ffonc.2018.00287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">"Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway</span></div><div class="casAuthors">Bousoik Emira; Montazeri Aliabadi Hamidreza; Bousoik Emira</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">287</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in signal transduction initiated by a wide range of membrane receptors.  Among the proteins in this family JAK2 has been associated with important downstream proteins, including signal transducers and activators of transcription (STATs), which in turn regulate the expression of a variety of proteins involved in induction or prevention of apoptosis.  Therefore, the JAK/STAT signaling axis plays a major role in the proliferation and survival of different cancer cells, and may even be involved in resistance mechanisms against molecularly targeted drugs.  Despite extensive research focused on the protein structure and mechanisms of activation of JAKs, and signal transduction through these proteins, their importance in cancer initiation and progression seem to be underestimated.  This manuscript is an attempt to highlight the role of JAK proteins in cancer biology, the most recent developments in targeting JAKs, and the central role they play in intracellular cross-talks with other signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-a-G-lYtjX0NHe_gFldTbfW6udTcc2eZjb2mlP0d4Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ot1Crtw%253D%253D&md5=ecda3b0ddfbfbea2a1d47b87ec0b52e3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00287%26sid%3Dliteratum%253Aachs%26aulast%3DBousoik%26aufirst%3DE.%26aulast%3DMontazeri%2BAliabadi%26aufirst%3DH.%26atitle%3DDo%2520we%2520know%2520jack%2520about%2520JAK%253F%2520A%2520closer%2520look%2520at%2520JAK%252FSTAT%2520signaling%2520pathway%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26doi%3D10.3389%2Ffonc.2018.00287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karantanos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, A. R.</span></span> <span> </span><span class="NLM_article-title">The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2018.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.blre.2018.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29627078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=426-432&author=T.+Karantanosauthor=A.+R.+Moliterno&title=The+roles+of+JAK2+in+DNA+damage+and+repair+in+the+myeloproliferative+neoplasms%3A+Opportunities+for+targeted+therapy&doi=10.1016%2Fj.blre.2018.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy</span></div><div class="casAuthors">Karantanos, Theodoros; Moliterno, Alison R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-432</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK2V617F-pos. myeloproliferative neoplasms (MPN) serve as an excellent model for the study of genomic instability accumulation during cancer progression.  Recent studies highlight the implication of JAK2 activating mutations in the development of DNA damage via reactive oxygen species (ROS) prodn., replication stress induction and the accumulation of genomic instability via the increased degrdn. of p53 and acquisition of a "mutagenic" phenotype.  The accumulation of genomic instability and acquisition of mutations in crit. DNA damage repair (DDR) mediators appears to be implicated in the progression of JAK2V617F-pos. MPN.  On the other hand, JAK2 signaling normally induces DDR through activation of repair mediators such as Chk1, RAD51 and RECQL5.  These opposing effects on DNA integrity in the setting of JAK2V617F have significant clin. implications and have led to the introduction of novel combinational therapies for these diseases.  The inhibition of MDM2 with Nutlin-3 improves the efficacy of IFN-α via decreased p53 degrdn., the combination of hydroxyurea with Ruxolitinib, and their combination with PARP inhibitors have significant anti-tumor effects.  A better understanding of the implication of JAK2 in the development and repair of DNA damage can improve our understanding of the biol. of these neoplasms, meliorate the risk stratification of our patients and enrich our therapeutic armamentarium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5c2DIOJxzLVg90H21EOLACvtfcHk0lih9rErRkVZVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVOisr8%253D&md5=67a26e3ed43b8ba4161694010cf40ce5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2018.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DKarantanos%26aufirst%3DT.%26aulast%3DMoliterno%26aufirst%3DA.%2BR.%26atitle%3DThe%2520roles%2520of%2520JAK2%2520in%2520DNA%2520damage%2520and%2520repair%2520in%2520the%2520myeloproliferative%2520neoplasms%253A%2520Opportunities%2520for%2520targeted%2520therapy%26jtitle%3DBlood%2520Rev.%26date%3D2018%26volume%3D32%26spage%3D426%26epage%3D432%26doi%3D10.1016%2Fj.blre.2018.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schieber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis in 2019: moving beyond JAK2 inhibition</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">74</span>, <span class="refDoi"> DOI: 10.1038/s41408-019-0236-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fs41408-019-0236-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=31511492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BB3MrnvVWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=74&author=M.+Schieberauthor=J.+D.+Crispinoauthor=B.+Stein&title=Myelofibrosis+in+2019%3A+moving+beyond+JAK2+inhibition&doi=10.1038%2Fs41408-019-0236-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis in 2019: moving beyond JAK2 inhibition</span></div><div class="casAuthors">Schieber Michael; Crispino John D; Stein Brady</div><div class="citationInfo"><span class="NLM_cas:title">Blood cancer journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia.  The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as a primary driver of MF, supporting a rationale for JAK inhibition.  However, JAK inhibition alone is insufficient for long-term remission and offers modest, if any, disease-modifying effects.  Given this, there is great interest in identifying mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies.  This review outlines the latest discoveries in the biology of MF, discusses current clinical management of patients with MF, and summarizes the ongoing clinical trials that hope to change the landscape of MF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ21BNrHUZ1BWLFM_lbR1VmfW6udTcc2eaxQPiwibKEo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrnvVWrtQ%253D%253D&md5=2b3376ccba1ca242430a5c5f6043a5e0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41408-019-0236-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41408-019-0236-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchieber%26aufirst%3DM.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26aulast%3DStein%26aufirst%3DB.%26atitle%3DMyelofibrosis%2520in%25202019%253A%2520moving%2520beyond%2520JAK2%2520inhibition%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2019%26volume%3D9%26spage%3D74%26doi%3D10.1038%2Fs41408-019-0236-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2721</span>– <span class="NLM_lpage">2730</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-11-395228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood-2011-11-395228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22279053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFalt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2721-2730&author=A.+Tefferi&title=JAK+inhibitors+for+myeloproliferative+neoplasms%3A+clarifying+facts+from+myths&doi=10.1182%2Fblood-2011-11-395228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2721-2730</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis.  This is welcome news for those patients in whom such therapy is indicated and treatment benefit outweighs attendant risk.  The question is who are these patients, what should they expect in terms of both short-term effects and long-term impact, and why would they choose ruxolitinib over other JAK inhibitors that are freely available for use in a research setting.  Ruxolitinib and most other JAK inhibitors exert a salutary effect on constitutional symptoms and splenomegaly but have yet to produce histopathol. or cytogenetic remissions, reverse bone marrow fibrosis, or improve survival over best supportive care.  Furthermore, the palliative value of JAK inhibitors is diminished by notable side effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities, peripheral neuropathy, and hyperacute relapse of symptoms during treatment discontinuation.  Therefore, risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera, outside of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoABjGudqibSbVg90H21EOLACvtfcHk0lhDmKfLsj2WSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFalt7s%253D&md5=441f2e6cd7b900b8ad9b385a742840b7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-395228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-395228%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DJAK%2520inhibitors%2520for%2520myeloproliferative%2520neoplasms%253A%2520clarifying%2520facts%2520from%2520myths%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2721%26epage%3D2730%26doi%3D10.1182%2Fblood-2011-11-395228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lhDmKfLsj2WSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span> <span> </span><span class="NLM_article-title">Fedratinib becomes new option in myelofibrosis</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1332&author=C.+Caruso&title=Fedratinib+becomes+new+option+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaruso%26aufirst%3DC.%26atitle%3DFedratinib%2520becomes%2520new%2520option%2520in%2520myelofibrosis%26jtitle%3DCancer%2520Discov.%26date%3D2019%26volume%3D9%26spage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">FDA approves Eli Lilly’s baricitinib</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=460&author=A.+Mullard&title=FDA+approves+Eli+Lilly%E2%80%99s+baricitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA vaccines get another booster</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1pR5FbMQvVLVg90H21EOLACvtfcHk0lho8ifYDYfeLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E&md5=025f07fb9a24835c5f349436f0372c10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520approves%2520Eli%2520Lilly%25E2%2580%2599s%2520baricitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2018%26volume%3D17%26spage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantschel, O.</span></span> <span> </span><span class="NLM_article-title">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fleu.2013.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23823659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=404-407&author=T.+Zhouauthor=S.+Georgeonauthor=R.+Moserauthor=D.+J.+Mooreauthor=A.+Caflischauthor=O.+Hantschel&title=Specificity+and+mechanism-of-action+of+the+JAK2+tyrosine+kinase+inhibitors+ruxolitinib+and+SAR302503+%28TG101348%29&doi=10.1038%2Fleu.2013.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)</span></div><div class="casAuthors">Zhou, T.; Georgeon, S.; Moser, R.; Moore, D. J.; Caflisch, A.; Hantschel, O.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">404-407</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-3vjA0n7DlLVg90H21EOLACvtfcHk0lho8ifYDYfeLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gtbk%253D&md5=7dbebd3eac60c3dd19026c9e3d3d3204</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.205%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DGeorgeon%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DSpecificity%2520and%2520mechanism-of-action%2520of%2520the%2520JAK2%2520tyrosine%2520kinase%2520inhibitors%2520ruxolitinib%2520and%2520SAR302503%2520%2528TG101348%2529%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D404%26epage%3D407%26doi%3D10.1038%2Fleu.2013.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamontanara, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gencer, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzyk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantschel, O.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1834</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bbapap.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23277196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1834&publication_year=2013&pages=1449-1459&author=A.+J.+Lamontanaraauthor=E.+B.+Gencerauthor=O.+Kuzykauthor=O.+Hantschel&title=Mechanisms+of+resistance+to+BCR-ABL+and+other+kinase+inhibitors&doi=10.1016%2Fj.bbapap.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span></div><div class="casAuthors">Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1834</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1449-1459</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  In this article, we are reviewing the mol. mechanisms that lead to kinase inhibitor resistance.  As the oncogenic BCR-ABL kinase is the target of the first approved small-mol. kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance.  We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients.  Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaBpN0j3KxrVg90H21EOLACvtfcHk0liir4_Wu6Bs9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D&md5=7706253e67a867b87ddadcec0bd5f972</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DLamontanara%26aufirst%3DA.%2BJ.%26aulast%3DGencer%26aufirst%3DE.%2BB.%26aulast%3DKuzyk%26aufirst%3DO.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520BCR-ABL%2520and%2520other%2520kinase%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2013%26volume%3D1834%26spage%3D1449%26epage%3D1459%26doi%3D10.1016%2Fj.bbapap.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almqvist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Molina, D.</span></span> <span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundbackauthor=P.+Nordlundauthor=D.+Martinez+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0liir4_Wu6Bs9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundback%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranfill, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0568-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1158%2F1535-7163.MCT-16-0568-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=28336808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1054-1067&author=S.+W.+Emberauthor=Q.+T.+Lambertauthor=N.+Berndtauthor=S.+Gunawanauthor=M.+Ayazauthor=M.+Tauroauthor=J.+Y.+Zhuauthor=P.+J.+Cranfillauthor=P.+Greningerauthor=C.+C.+Lynchauthor=C.+H.+Benesauthor=H.+R.+Lawrenceauthor=G.+W.+Reutherauthor=N.+J.+Lawrenceauthor=E.+Schonbrunn&title=Potent+dual+BET+bromodomain-kinase+inhibitors+as+value-added+multitargeted+chemical+probes+and+cancer+therapeutics&doi=10.1158%2F1535-7163.MCT-16-0568-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span></div><div class="casAuthors">Ember, Stuart W.; Lambert, Que T.; Berndt, Norbert; Gunawan, Steven; Ayaz, Muhammad; Tauro, Marilena; Zhu, Jin-Yi; Cranfill, Paula J.; Greninger, Patricia; Lynch, Conor C.; Benes, Cyril H.; Lawrence, Harshani R.; Reuther, Gary W.; Lawrence, Nicholas J.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1054-1067</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers.  Using the chem. scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1.  Lead compds. showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm.  Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1.  Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing.  Combined, our findings indicate promising potential of these agents as novel chem. probes and cancer therapeutics.  Mol Cancer Ther; 16(6); 1054-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFXcj0XbzGLVg90H21EOLACvtfcHk0liir4_Wu6Bs9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D&md5=1c0a838978c931fd8ad148a6696bda26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0568-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0568-T%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DAyaz%26aufirst%3DM.%26aulast%3DTauro%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DCranfill%26aufirst%3DP.%2BJ.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DC.%2BC.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DPotent%2520dual%2520BET%2520bromodomain-kinase%2520inhibitors%2520as%2520value-added%2520multitargeted%2520chemical%2520probes%2520and%2520cancer%2520therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1054%26epage%3D1067%26doi%3D10.1158%2F1535-7163.MCT-16-0568-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quentmeier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaborski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H. G.</span></span> <span> </span><span class="NLM_article-title">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fsj.leu.2404081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=16408098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Kjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=471-476&author=H.+Quentmeierauthor=R.+A.+MacLeodauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=JAK2+V617F+tyrosine+kinase+mutation+in+cell+lines+derived+from+myeloproliferative+disorders&doi=10.1038%2Fsj.leu.2404081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span></div><div class="casAuthors">Quentmeier, H.; MacLeod, R. A. F.; Zaborski, M.; Drexler, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mutation in the JH2 pseudokinase domain of the Janus kinase 2 gene (JAK2 V617F) has been described in chronic myeloproliferative disorders (MPD).  We screened 79 acute myeloid leukemia (AML) cell lines and found five pos. for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS.  While SET-2 expressed both mutant (mu) and wild-type (wt) JAK2, remaining positives carried homo-/hemizygous JAK2 mutations.  Microsatellite anal. confirmed losses of heterozygosity (LOH) affecting the JAK2 region on chromosome 9p in MB-02, MUTZ-8 and UKE-1, but also in HEL, the only JAK2mu cell line lacking any reported MPD/MDS history.  All five JAK2mu cell lines displayed cytogenetic hallmarks of MDS, namely losses of 5q or 7q, remarkably in 4/5 cases affecting both chromosomes.  Our combined FISH and microsatellite anal. uncovered a novel mechanism to supplement mitotic recombination previously proposed to explain JAK2 LOH, namely chromosome deletion with/without selective JAK2mu amplification.  Confirming the importance of the mutated JAK2 protein for growth and prevention of apoptosis, JAK2mu cell lines displayed higher sensitivities to JAK2 inhibition than JAK2wt cell lines.  In summary, JAK2 V617F cell lines, derived from patients with history of MPD/MDS, represent novel research tools for elucidating the pathobiol. of this JAK2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbWLZTI7h7Vg90H21EOLACvtfcHk0lhBcLlnp2Z_Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Kjtbo%253D&md5=b75412e3ac608626fac7666b0e9a9a2c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404081%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DJAK2%2520V617F%2520tyrosine%2520kinase%2520mutation%2520in%2520cell%2520lines%2520derived%2520from%2520myeloproliferative%2520disorders%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fsj.leu.2404081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. G.</span></span> <span> </span><span class="NLM_article-title">c-Src binds to the cancer drug Ruxolitinib with an active conformation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e106225</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0106225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1371%2Fjournal.pone.0106225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25197973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOju7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=Y.+Duanauthor=L.+Chenauthor=Y.+Chenauthor=X.+G.+Fan&title=c-Src+binds+to+the+cancer+drug+Ruxolitinib+with+an+active+conformation&doi=10.1371%2Fjournal.pone.0106225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src binds to the cancer drug Ruxolitinib with an active conformation</span></div><div class="casAuthors">Duan, Yankun; Chen, Lin; Chen, Yongheng; Fan, Xue-Gong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e106225/1-e106225/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms.  In addn., Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.  There is no structural information of Ruxolitinib binding to any kinase.  In this paper, we detd. the crystal structure of c-Src kinase domain in complex of Ruxolitinib at a resoln. of 2.26 Å.  C-Src kinase domain adopts the DFG-in active conformation upon Ruxolitinib binding, indicating Ruxolitinib is a type I inhibitor for c-Src.  Ruxolitinib forms two hydrogen bonds with Met341, a water-mediated hydrogen bond with Thr338 and a no. of van der Waals contacts with c-Src.  Ruxolitinib was then docked into the ligand-binding pocket of a previously solved JAK1 structure.  From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.  Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnUlK89E7xArVg90H21EOLACvtfcHk0lhBcLlnp2Z_Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOju7bK&md5=6786a81e8bef0d881523902144b833b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0106225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0106225%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DX.%2BG.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520Ruxolitinib%2520with%2520an%2520active%2520conformation%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0106225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ligH5JPeo5q-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightle, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span> <span> </span><span class="NLM_article-title">Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.pep.2009.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.pep.2009.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=19781647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2010&pages=54-63&author=T.+Hallauthor=T.+L.+Emmonsauthor=J.+E.+Chrencikauthor=J.+A.+Gormleyauthor=R.+A.+Weinbergauthor=J.+W.+Leoneauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+F.+Schindlerauthor=J.+E.+Dayauthor=J.+M.+Williamsauthor=J.+R.+Kieferauthor=S.+A.+Lightleauthor=M.+S.+Harrisauthor=S.+Guruauthor=H.+D.+Fischerauthor=A.+G.+Tomasselli&title=Expression%2C+purification%2C+characterization+and+crystallization+of+non-+and+phosphorylated+states+of+JAK2+and+JAK3+kinase+domain&doi=10.1016%2Fj.pep.2009.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain</span></div><div class="casAuthors">Hall, Troii; Emmons, Thomas L.; Chrencik, Jill E.; Gormley, Jennifer A.; Weinberg, Robin A.; Leone, Joseph W.; Hirsch, Jeffrey L.; Saabye, Matthew J.; Schindler, John F.; Day, Jacqueline E.; Williams, Jennifer M.; Kiefer, James R.; Lightle, Sandra A.; Harris, Melissa S.; Guru, Siradanahalli; Fischer, H. David; Tomasselli, Alfredo G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression & Purification</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus-assocd. kinases (JAKs) play crit. roles in cytokine signaling, and have emerged as viable therapeutic targets in inflammation and oncol. related diseases.  To date, targeting JAK proteins with highly selective inhibitor compds. have remained elusive.  We have expressed the active kinase domains for both JAK2 and JAK3 and devised purifn. protocols to resolve the non-, mono- (Y1007) and diphosphorylated (Y1007 and Y1008) states of JAK2 and non- and monophosphorylated states of JAK3 (Y980).  An optimal purified protein yield of 20, 29 and 69 mg per 20 L cell culture was obtained for the three JAK2 forms, resp., and 12.2 and 2.3 mg per 10 L fermn. for the two JAK3 forms allowing detailed biochem. and biophys. studies.  To monitor the purifn. process we developed a novel HPLC activity assay where a sequential order of phosphorylation was obsd. whereby the first tyrosine residue was completely phosphorylated prior to phosphorylation of the tandem tyrosine residue.  A Caliper-based microfluidics assay was used to det. the kinetic parameters (K m and kcat) for each phosphorylated state, showing that monophosphorylated (Y1007) JAK2 enzyme activity increased 9-fold over that of the nonphosphorylated species, and increased an addnl. 6-fold for the diphosphorylated (Y1007/Y1008) species, while phosphorylation of JAK3 resulted in a negligible increase in activity.  Moreover, crystal structures have been generated for each isolated state of JAK2 and JAK3 with resolns. better than 2.4 Å.  The generation of these reagents has enabled kinetic and structural characterization to inform the design of potent and selective inhibitors of the JAK family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb5gEwPDT4LVg90H21EOLACvtfcHk0ligH5JPeo5q-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrtLjF&md5=ae884695b3fb546edbed762d65b74ad3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pep.2009.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pep.2009.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DT.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLightle%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DM.%2BS.%26aulast%3DGuru%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26atitle%3DExpression%252C%2520purification%252C%2520characterization%2520and%2520crystallization%2520of%2520non-%2520and%2520phosphorylated%2520states%2520of%2520JAK2%2520and%2520JAK3%2520kinase%2520domain%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2010%26volume%3D69%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.pep.2009.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2809</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bmcl.2015.04.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25987372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2809-2812&author=K.+Zimmermannauthor=X.+Sangauthor=H.+A.+Mastalerzauthor=W.+L.+Johnsonauthor=G.+Zhangauthor=Q.+Liuauthor=D.+Battauthor=L.+J.+Lombardoauthor=D.+Vyasauthor=G.+L.+Trainorauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=M.+M.+Gottardisauthor=J.+Lippyauthor=J.+Khanauthor=J.+S.+Sackauthor=A.+V.+Purandare&title=9H-Carbazole-1-carboxamides+as+potent+and+selective+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors</span></div><div class="casAuthors">Zimmermann, Kurt; Sang, Xiaopeng; Mastalerz, Harold A.; Johnson, Walter L.; Zhang, Guifen; Liu, Qingjie; Batt, Douglas; Lombardo, Louis J.; Vyas, Dinesh; Trainor, George L.; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; Gottardis, Marco M.; Lippy, Jonathan; Khan, Javed; Sack, John S.; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2809-2812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed.  Optimization for JAK family selectivity led to compds. I and II, with greater than 45-fold selectivity for JAK2 over all other members of the JAK kinase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ4DLKQOU6vLVg90H21EOLACvtfcHk0lg_5lNE4cGQ7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGktr0%253D&md5=bbe6542426b0da0ae8938cd55a395b3c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.101%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DMastalerz%26aufirst%3DH.%2BA.%26aulast%3DJohnson%26aufirst%3DW.%2BL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DVyas%26aufirst%3DD.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3D9H-Carbazole-1-carboxamides%2520as%2520potent%2520and%2520selective%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2809%26epage%3D2812%26doi%3D10.1016%2Fj.bmcl.2015.04.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.+B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfo+namide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lhmcSHZ5dI2EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfo%2520namide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6176</span>– <span class="NLM_lpage">6193</span>, <span class="refDoi"> DOI: 10.1021/jm300628c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+Devossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavailable+JAK1+inhibitors+with+selectivity+over+JAK2&doi=10.1021%2Fjm300628c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Mendonca, Rohan; Balazs, Mercedesz; Barrett, Kathy; Bergeron, Philippe; Blair, Wade S.; Chang, Christine; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Hamman, Chris; Hanan, Emily J.; Harstad, Eric; Hewitt, Peter R.; Hurley, Christopher A.; Jin, Tian; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Kulagowski, Janusz J.; Labadie, Sharada; Liao, Jiangpeng; Liimatta, Marya; Lin, Zhonghua; Lupardus, Patrick J.; Maxey, Robert J.; Murray, Jeremy M.; Pulk, Rebecca; Rodriguez, Madeleine; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Xiao, Ling; Xiao, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6176-6193</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the discovery of the C-2 Me substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.  The C-2 Me substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compd. 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochem. and cell-based assays, resp.).  Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated.  Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20).  Details of the biol. characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclin. in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogQqQMRvwKbVg90H21EOLACvtfcHk0lgU6vW1kKBcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D&md5=8c57a4cb02fc245ed12f6f4efdb82318</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDevoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193%26doi%3D10.1021%2Fjm300628c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span>; <span class="NLM_string-name">Zhu, H.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Tian, G.</span></span> <span> </span><span class="NLM_article-title">Intermediate of JAK inhibitor and preparation method thereof</span>.  <i>China patent</i> <span class="NLM_year">2018</span><b>,</b> <span class="NLM_patent">CN107759623A</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+Cao&author=H.+Zhu&author=J.+Wu&author=G.+Tian&title=Intermediate+of+JAK+inhibitor+and+preparation+method+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DB.%26atitle%3DIntermediate%2520of%2520JAK%2520inhibitor%2520and%2520preparation%2520method%2520thereof%26jtitle%3DChina%2520patent%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knouse, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, W. M.</span></span> <span> </span><span class="NLM_article-title">Diverted total synthesis of promysalin analogs demonstrates that an iron-binding motif is responsible for its narrow-spectrum antibacterial activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5836</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b03373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b03373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=5833-5836&author=A.+D.+Steeleauthor=C.+E.+Keohaneauthor=K.+W.+Knouseauthor=S.+E.+Rossiterauthor=S.+J.+Williamsauthor=W.+M.+Wuest&title=Diverted+total+synthesis+of+promysalin+analogs+demonstrates+that+an+iron-binding+motif+is+responsible+for+its+narrow-spectrum+antibacterial+activity&doi=10.1021%2Fjacs.6b03373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diverted Total Synthesis of Promysalin Analogs Demonstrates That an Iron-Binding Motif Is Responsible for Its Narrow-Spectrum Antibacterial Activity</span></div><div class="casAuthors">Steele, Andrew D.; Keohane, Colleen E.; Knouse, Kyle W.; Rossiter, Sean E.; Williams, Sierra J.; Wuest, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5836</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Promysalin (I) is a species-specific Pseudomonad metabolite with unique bioactivity.  To better understand the mode of action of this natural product, we synthesized 16 analogs utilizing diverted total synthesis (DTS).  Our analog studies revealed that the bioactivity of promysalin is sensitive to changes within its hydrogen bond network whereby alteration has drastic biol. consequences.  The DTS library not only yielded three analogs that retained potency but also provided insights that resulted in the identification of a previously unknown ability of promysalin to bind iron.  These findings coupled with previous observations hint at a complex multifaceted role of the natural product within the rhizosphere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL9HadENBaPrVg90H21EOLACvtfcHk0lgU6vW1kKBcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsLk%253D&md5=79c9be41f340fe1a194f8e05c1a1e19e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b03373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b03373%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DA.%2BD.%26aulast%3DKeohane%26aufirst%3DC.%2BE.%26aulast%3DKnouse%26aufirst%3DK.%2BW.%26aulast%3DRossiter%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DWuest%26aufirst%3DW.%2BM.%26atitle%3DDiverted%2520total%2520synthesis%2520of%2520promysalin%2520analogs%2520demonstrates%2520that%2520an%2520iron-binding%2520motif%2520is%2520responsible%2520for%2520its%2520narrow-spectrum%2520antibacterial%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D5833%26epage%3D5836%26doi%3D10.1021%2Fjacs.6b03373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lgU6vW1kKBcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bmcl.2018.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29945795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2636-2640&author=L.+Yaoauthor=P.+M.+Ramanujuluauthor=A.+Poulsenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Merging+of+ruxolitinib+and+vorinostat+leads+to+highly+potent+inhibitors+of+JAK2+and+histone+deacetylase+6+%28HDAC6%29&doi=10.1016%2Fj.bmcl.2018.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span></div><div class="casAuthors">Yao, Lianbin; Ramanujulu, Pondy Murugappan; Poulsen, Anders; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2636-2640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of more than one pathway in a cancer cell with a single mol. could result in better therapies with less complex dosing regimens.  In this work multi-component ligands have been prepd. by joining together key pharmacophores of two different enzyme inhibitors in a way which increases potency against the individual pathways.  Selective JAK1/2 inhibitor, ruxolitinib (3), and pan-HDAC inhibitor vorinostat (4) were linked together by a single nitrogen atom to create a new series of compds. with very potent JAK2 and HDAC6 inhibition with selectivity against HDAC1.  A preferred compd., I, had unprecedented sub-nanomolar JAK2 potency with an IC50 of 41 pM and a sub-nanomolar IC50 against HDAC6 of 200 pM.  Binding models show a good fit into both JAK2 and HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3j4Hop3jqrVg90H21EOLACvtfcHk0liDDRG_B9MrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M&md5=78776f7cd6ac7384c701edd2fd4a6940</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DMerging%2520of%2520ruxolitinib%2520and%2520vorinostat%2520leads%2520to%2520highly%2520potent%2520inhibitors%2520of%2520JAK2%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2636%26epage%3D2640%26doi%3D10.1016%2Fj.bmcl.2018.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akri-Topoulou-Zanze, I.</span>; <span class="NLM_string-name">Wakefield, B. D.</span>; <span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Turner, S. C.</span>; <span class="NLM_string-name">Gasiecki, A. F.</span>; <span class="NLM_string-name">Gracias, V. J.</span>; <span class="NLM_string-name">Sarris Kathy, A.</span>; <span class="NLM_string-name">Kalvin, D. M.</span>; <span class="NLM_string-name">Michmerhuizen, M. J.</span>; <span class="NLM_string-name">Shuai, Q.</span>; <span class="NLM_string-name">Patel, J. R.</span>; <span class="NLM_string-name">Bakker, M.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Johnson, E. T.</span>; <span class="NLM_string-name">Kovar, P. J.</span>; <span class="NLM_string-name">Djuric, S. W.</span>; <span class="NLM_string-name">Long, A. J.</span>; <span class="NLM_string-name">Vasudevan, A.</span>; <span class="NLM_string-name">George, D.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">St. John Moore, N.</span>; <span class="NLM_string-name">Hobson, A. D.</span>; <span class="NLM_string-name">Woods, K. W.</span>; <span class="NLM_string-name">Miyashiro, J. M.</span>; <span class="NLM_string-name">Swann, S. L. J.</span>; <span class="NLM_string-name">Penning, T. D.</span></span> <span> </span><span class="NLM_article-title">5-Substituted Indazoles as Kinase Inhibitors</span>. US patent <span class="NLM_year">2014</span>, <span class="NLM_patent">8,648,069B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=I.+Akri-Topoulou-Zanze&author=B.+D.+Wakefield&author=H.+Mack&author=S.+C.+Turner&author=A.+F.+Gasiecki&author=V.+J.+Gracias&author=A.+Sarris+Kathy&author=D.+M.+Kalvin&author=M.+J.+Michmerhuizen&author=Q.+Shuai&author=J.+R.+Patel&author=M.+Bakker&author=N.+Teusch&author=E.+T.+Johnson&author=P.+J.+Kovar&author=S.+W.+Djuric&author=A.+J.+Long&author=A.+Vasudevan&author=D.+George&author=L.+Wang&author=B.+Li&author=N.+St.+John+Moore&author=A.+D.+Hobson&author=K.+W.+Woods&author=J.+M.+Miyashiro&author=S.+L.+J.+Swann&author=T.+D.+Penning&title=5-Substituted+Indazoles+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAkri-Topoulou-Zanze%26aufirst%3DI.%26atitle%3D5-Substituted%2520Indazoles%2520as%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Liu, P.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Metcalf, B. W.</span>; <span class="NLM_string-name">Meloni, D.</span>; <span class="NLM_string-name">Pan, Y.</span>; <span class="NLM_string-name">Xia, M.</span>; <span class="NLM_string-name">Li, M.</span>; <span class="NLM_string-name">Yue, T.-Y.</span>; <span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing JAK Inhibitors and Related Compounds</span>. US patent <span class="NLM_year">2013</span>, <span class="NLM_patent">US8,410,265B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Zhou&author=P.+Liu&author=Q.+Lin&author=B.+W.+Metcalf&author=D.+Meloni&author=Y.+Pan&author=M.+Xia&author=M.+Li&author=T.-Y.+Yue&author=J.+D.+Rodgers&author=H.+Wang&title=Processes+for+Preparing+JAK+Inhibitors+and+Related+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DProcesses%2520for%2520Preparing%2520JAK%2520Inhibitors%2520and%2520Related%2520Compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akri-Topoulou-Zanze, I.</span>; <span class="NLM_string-name">Wakefield, B. D.</span>; <span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Turner, S. C.</span>; <span class="NLM_string-name">Gasiecki, A. F.</span>; <span class="NLM_string-name">Gracias, V. J.</span>; <span class="NLM_string-name">Kathy, S.</span>; <span class="NLM_string-name">Kalvin, D. M.</span>; <span class="NLM_string-name">Michmerhuizen, M. J.</span>; <span class="NLM_string-name">Shuai, Q.</span>; <span class="NLM_string-name">Patel, J. R.</span>; <span class="NLM_string-name">Bakker, M.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Johnson, E. T.</span>; <span class="NLM_string-name">Kovar, P. J.</span>; <span class="NLM_string-name">Djuric, S. W.</span>; <span class="NLM_string-name">Long, A. J.</span>; <span class="NLM_string-name">Vasude-Van, A.</span>; <span class="NLM_string-name">Hobson, A.</span>; <span class="NLM_string-name">St. John Moore, N.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">George, D.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Frank, K.</span></span> <span> </span><span class="NLM_article-title">5-Heteroaryl Substituted Indazoles as Kinase Inhibitors</span>. PCT patent application <span class="NLM_year">2013</span>, <span class="NLM_patent">WO2008/154241A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=I.+Akri-Topoulou-Zanze&author=B.+D.+Wakefield&author=H.+Mack&author=S.+C.+Turner&author=A.+F.+Gasiecki&author=V.+J.+Gracias&author=S.+Kathy&author=D.+M.+Kalvin&author=M.+J.+Michmerhuizen&author=Q.+Shuai&author=J.+R.+Patel&author=M.+Bakker&author=N.+Teusch&author=E.+T.+Johnson&author=P.+J.+Kovar&author=S.+W.+Djuric&author=A.+J.+Long&author=A.+Vasude-Van&author=A.+Hobson&author=N.+St.+John+Moore&author=L.+Wang&author=D.+George&author=B.+Li&author=K.+Frank&title=5-Heteroaryl+Substituted+Indazoles+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAkri-Topoulou-Zanze%26aufirst%3DI.%26atitle%3D5-Heteroaryl%2520Substituted%2520Indazoles%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span>; <span class="NLM_string-name">Lawrence, N. J.</span>; <span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">BRD4-JAK2 Inhibitors</span>. PCT patent application <span class="NLM_year">2020</span>, <span class="NLM_patent">WO2020/051572</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Schonbrunn&author=N.+J.+Lawrence&author=H.+R.+Lawrence&title=BRD4-JAK2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DBRD4-JAK2%2520Inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span>; <span class="NLM_string-name">Lawrence, N. J.</span>; <span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">Potent Dual BRD4-Kinase Inhibitors as Cancer Therapeutics</span>.  <i>US patent</i> <span class="NLM_year">2018</span><b>,</b> <span class="NLM_patent">US10,106,507B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Schonbrunn&author=N.+J.+Lawrence&author=H.+R.+Lawrence&title=Potent+Dual+BRD4-Kinase+Inhibitors+as+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DPotent%2520Dual%2520BRD4-Kinase%2520Inhibitors%2520as%2520Cancer%2520Therapeutics%26jtitle%3DUS%2520patent%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ruxolitinib enhances the expression and purification of crystallization-grade JAK2 KD. (A) Expi293F cells were transiently transfected with wild-type JAK2 KD. Cells were treated with increasing concentrations of ruxolitinib during the 24-hour transfection. Cell lysates were subjected to immunoblotting to detect phosphorylated and unphosphorylated JAK2 KD along with the loading control GAPDH. Densitometry of the western blot is depicted as a bar graph. (B) Same as (A) except 2 mM and 4 mM butyric acid (BA) or valproic acid (VPA) were added to cells with 1 μM ruxolitinib. (C) Expi293F cells were transiently transfected with JAK2 KD +/– 1 μM ruxolitinib and analyzed by CETSA. Cells were incubated at the indicated temperatures for 3 min, and lysates were probed for JAK2 KD and the loading control actin. The graph shows the densitometry values relative to the loading control as a function of temperature. Data were fit to a four-parameter Hill equation, yielding EC<sub>50</sub> values of 45 and 47 °C for JAK2 KD expressed in the absence and presence of ruxolitinib, respectively. (D) Cells were grown as in (C) for ITDR against ruxolitinib at 47 °C for 3 min, and cell lysates were probed for JAK2 and GAPDH. The corresponding densitometry values were fit to a four-parameter Hill equation yielding EC<sub>50</sub> = 3.8 μM. (E) SDS-PAGE of typical purification of JAK2 KD from 1 L of Expi293F cell culture grown in the presence of 1 μM ruxolitinib and 4 mM BA for 24 h. Lane 1 GenScript broad range ladder, Lane 2 soluble lysate, Lane 3 GE HisTrap flow-through, Lane 4 GE HisTrap elution peak, and Lane 5 GE S75 elution peak. (F) Photograph of X-ray-grade crystals grown from thus purified JAK2 KD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Purified JAK2 KD from Expi293 cells is suitable for SAR studies by DSF. Three series of JAK2 inhibitors were subjected to SAR studies: (A) Ruxolitinib stereoisomers and FDA-approved derivatives, (B) piperidine–phenylamine analogues of ruxolitinib, and (C) fedratinib and derived dual JAK2–BRD4 inhibitors. (D) DSF derivative plots of JAK2 KD in the absence (DMSO) and presence of 100 μM inhibitor. (E) Viability of UKE-1 cells in response to increasing inhibitor concentration. (F) DSF and biochemical enzyme inhibition data correlate significantly. (G) Analysis of DSF and UKE-1 cell growth inhibition data shows high correlation for series A, but not for series B and C. Series B likely suffers from poor cell permeability. (H) For series C, cell inhibition data correlate significantly with the binding potential for BRD4-1, suggesting a predominant activity through inhibition of BRD4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis of ruxolitinib interaction with JAK2. Cocrystal structure of JAK2 KD liganded with ruxolitinib determined at 1.9 Å resolution (PDB 6VGL). (A) Electrostatic surface potential of the JAK2–ruxolitinib complex. The inhibitor is shown as yellow spheres. (B) Positioning of ruxolitinib in the ATP site. The hinge region is shown in orange, gatekeeper residue in red, DFG motif in green, P-loop in cyan, C-helix in magenta, and other residues in grey. (C) Binding interactions of ruxolitinib in the ATP site. Potential H-bonding and hydrophobic vdW interactions are indicated as black and green dotted lines, respectively. (D) 2Fo–Fc electron density map (1σ) of bound ruxolitinib at 1.9 Å resolution. (E) Binding pose of ruxolitinib (beige) in c-SRC (PDB 4U5J) and upon superposition with ruxolitinib in JAK2 (yellow). (F) 1.9 Å resolution cocrystal structure of JAK2 with baricitinib (magenta, PDB 6VN8) and superposition with ruxolitinib (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. JAK2 discriminates between the (<i>R</i>)<i>-</i> and (<i>S</i>)-stereoisomers of ruxolitinib and derivatives thereof. Distinct stereoisomers and the enantiomeric mixture of ruxolitinib and derivatives were subjected to crystallographic studies with JAK2 KD. (A) Cocrystal structure of (<i>S</i>)-ruxolitinib (PDB 6VSN). (B) Superposition of the (<i>R</i>)- and (<i>S</i>)-isomers of ruxolitinib (yellow and cyan, respectively) reveals that (<i>S</i>)-ruxolitinib adopts shape complementarity with the ATP site through ∼180° rotation about the stereocenter. (C) Cocrystal structure obtained with the racemic mixture of ruxolitinib, (<i>rac</i>)-ruxolitinib (PDB 6VNK) reveals only the (<i>R</i>)-isomer bound (green). The inset shows the superposition of (<i>rac</i>)-ruxolitinib with ruxolitinib. (D) Cocrystal structure showing the H-bonding interactions of (<i>R</i>)-<b>1</b> (yellow, PDB 6VNC) with the hinge region. (E) Same as (D) for the (<i>S</i>)<i>-</i><b>1</b> (cyan, PDB 6VNB). (F) Superposition of (<i>R</i>)-<b>1</b> and (<i>S</i>)-<b>1</b> reveals the same adaptation as for ruxolitinib (B). (G) Cocrystal structure obtained with (<i>rac</i>)-<b>1</b> (green, PDB 6VS3) shows only the (<i>R</i>)-isomer bound. The inset shows the superposition of (<i>rac</i>)-<b>1</b> with (<i>R</i>)-<b>1</b> (yellow). (H) Cocrystal structure with derivative <b>2</b> devoid of a stereocenter (PDB 6VNJ) reveals the same binding pose and inhibitor conformation as (<i>R</i>)-<b>1</b>. (I) Same as (H) for derivative <b>3</b> (PDB 6VNM). The blue mesh is the 2Fo–Fc electron density of ligand contoured at 1σ. The electron density maps upon refinement omitting the ligand are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf" class="ext-link">Figure S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/medium/jm0c01952_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Diaminopyrimidine inhibitors mimic the binding pose of ruxolitinib–aniline derivatives. (A) Cocrystal structure of JAK2 with fedratinib (PDB 6VNE). The inset shows the superposition of fedratinib (yellow) with (<i>R</i>)-<b>1</b> (magenta). (B) Cocrystal structure with <b>4</b> (PDB 6VNG). The inset shows the superposition of <b>4</b> (yellow) with fedratinib (green). (C) Cocrystal structure with <b>5</b> (PDB 6VNH). (D) Cocrystal structure with <b>6</b> (PDB 6VNL). (E) Cocrystal structure with <b>7</b> (PDB 6VNF).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01952/20210218/images/large/jm0c01952_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01952&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span> <span> </span><span class="NLM_article-title">Cancer genome landscapes</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1126/science.1235122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1126%2Fscience.1235122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23539594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=1546-1558&author=B.+Vogelsteinauthor=N.+Papadopoulosauthor=V.+E.+Velculescuauthor=S.+Zhouauthor=L.+A.+Diazauthor=K.+W.+Kinzler&title=Cancer+genome+landscapes&doi=10.1126%2Fscience.1235122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer genome landscapes</span></div><div class="casAuthors">Vogelstein, Bert; Papadopoulos, Nickolas; Velculescu, Victor E.; Zhou, Shibin; Diaz, Luis A., Jr.; Kinzler, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6127</span>),
    <span class="NLM_cas:pages">1546-1558</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer.  For most cancer types, this landscape consists of a small no. of "mountains" (genes altered in a high percentage of tumors) and a much larger no. of "hills" (genes altered infrequently).  To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or "drive" tumorigenesis.  A typical tumor contains two to eight of these "driver gene" mutations; the remaining mutations are passengers that confer no selective growth advantage.  Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance.  A better understanding of these pathways is one of the most pressing needs in basic cancer research.  Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXBcf6dWj0bVg90H21EOLACvtfcHk0lifzx4OY5rA1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOhsb0%253D&md5=da190782f210873557cbf15441540ee7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1235122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1235122%26sid%3Dliteratum%253Aachs%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DCancer%2520genome%2520landscapes%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D1546%26epage%3D1558%26doi%3D10.1126%2Fscience.1235122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into regulation of JAK2 tyrosine kinase</span>. <i>Front. Endocrinol. (Lausanne)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.3389%2Ffendo.2017.00361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29379470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvlt1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=361&author=S.+R.+Hubbard&title=Mechanistic+insights+into+regulation+of+JAK2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase</span></div><div class="casAuthors">Hubbard Stevan R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">361</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">JAK2 is a member of the Janus kinase (JAKs) family of non-receptor protein tyrosine kinases, which includes JAK1-3 and TYK2.  JAKs serve as the cytoplasmic signaling components of cytokine receptors and are activated through cytokine-mediated trans-phosphorylation, which leads to receptor phosphorylation and recruitment and phosphorylation of signal transducer and activator of transcription (STAT) proteins.  JAKs are unique among tyrosine kinases in that they possess a pseudokinase domain, which is just upstream of the C-terminal tyrosine kinase domain.  A wealth of biochemical and clinical data have established that the pseudokinase domain of JAKs is crucial for maintaining a low basal (absence of cytokine) level of tyrosine kinase activity.  In particular, gain-of-function mutations in the JAK genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.  Recent structural and biochemical studies have begun to decipher the molecular mechanisms that maintain the basal, low-activity state of JAKs and that, via mutation, lead to constitutive activity and disease.  This review will examine these mechanisms and describe how this knowledge could potentially inform drug development efforts aimed at obtaining a mutant (V617F)-selective inhibitor of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRk0uCTffMr3-2qxNLjzXe8fW6udTcc2eZS8ZUJiavMyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvlt1GgsQ%253D%253D&md5=1c051c523530ee188e915763c7651679</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2017.00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2017.00361%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DMechanistic%2520insights%2520into%2520regulation%2520of%2520JAK2%2520tyrosine%2520kinase%26jtitle%3DFront.%2520Endocrinol.%2520%2528Lausanne%2529%26date%3D2017%26volume%3D8%26spage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesarwani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kincaid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evelyn, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesiada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span> <span> </span><span class="NLM_article-title">Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">14538</span> <span class="refDoi"> DOI: 10.1038/srep14538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fsrep14538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=26419724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=M.+Kesarwaniauthor=E.+Huberauthor=Z.+Kincaidauthor=C.+R.+Evelynauthor=J.+Biesiadaauthor=M.+Ranceauthor=M.+B.+Thapaauthor=N.+P.+Shahauthor=J.+Mellerauthor=Y.+Zhengauthor=M.+Azam&title=Targeting+substrate-site+in+Jak2+kinase+prevents+emergence+of+genetic+resistance&doi=10.1038%2Fsrep14538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance</span></div><div class="casAuthors">Kesarwani, Meenu; Huber, Erika; Kincaid, Zachary; Evelyn, Chris R.; Biesiada, Jacek; Rance, Mark; Thapa, Mahendra B.; Shah, Neil P.; Meller, Jarek; Zheng, Yi; Azam, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14538</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Emergence of genetic resistance against kinase inhibitors poses a great challenge for durable therapeutic response.  Here, we report a novel mechanism of JAK2 kinase inhibition by fedratinib (TG101348) that prevents emergence of genetic resistance.  Using in vitro drug screening, we identified 211 amino-acid substitutions conferring resistance to ruxolitinib (INCB018424) and cross-resistance to the JAK2 inhibitors AZD1480, CYT-387 and lestaurtinib.  In contrast, these resistant variants were fully sensitive to fedratinib.  Structural modeling, coupled with mutagenesis and biochem. studies, revealed dual binding sites for fedratinib.  In vitro binding assays using purified proteins showed strong affinity for the substrate-binding site (Kd = 20 nM) while affinity for the ATP site was poor (Kd = ∼8 μM).  Our studies demonstrate that mutations affecting the substrate-binding pocket encode a catalytically incompetent kinase, thereby preventing emergence of resistant variants.  Most importantly, our data suggest that in order to develop resistance-free kinase inhibitors, the next-generation drug design should target the substrate-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRRslm0pE7PrVg90H21EOLACvtfcHk0lj3E9KIsaYp9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ks7rE&md5=f4cab9a5e41db436796b0e0aedd4d105</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsrep14538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep14538%26sid%3Dliteratum%253Aachs%26aulast%3DKesarwani%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DE.%26aulast%3DKincaid%26aufirst%3DZ.%26aulast%3DEvelyn%26aufirst%3DC.%2BR.%26aulast%3DBiesiada%26aufirst%3DJ.%26aulast%3DRance%26aufirst%3DM.%26aulast%3DThapa%26aufirst%3DM.%2BB.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DMeller%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26atitle%3DTargeting%2520substrate-site%2520in%2520Jak2%2520kinase%2520prevents%2520emergence%2520of%2520genetic%2520resistance%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep14538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+activation+as+a+mechanism+of+persistence+to+JAK2+inhibitor+therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0lh2YdwUh3DLaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520activation%2520as%2520a%2520mechanism%2520of%2520persistence%2520to%2520JAK2%2520inhibitor%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorantla, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib mediated paradox JAK2 hyperphosphorylation is due to the protection of activation loop phosphotyrosines from phosphatases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>, <span class="NLM_elocation-id">2847</span> <span class="refDoi"> DOI: 10.1182/blood.V122.21.2847.2847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood.V122.21.2847.2847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&author=S.+P.+Gorantlaauthor=K.+S.+Babuauthor=A.+L.+Illertauthor=N.+von+Bubnoffauthor=C.+Peschelauthor=J.+Duyster&title=Ruxolitinib+mediated+paradox+JAK2+hyperphosphorylation+is+due+to+the+protection+of+activation+loop+phosphotyrosines+from+phosphatases&doi=10.1182%2Fblood.V122.21.2847.2847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood.V122.21.2847.2847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V122.21.2847.2847%26sid%3Dliteratum%253Aachs%26aulast%3DGorantla%26aufirst%3DS.%2BP.%26aulast%3DBabu%26aufirst%3DK.%2BS.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520mediated%2520paradox%2520JAK2%2520hyperphosphorylation%2520is%2520due%2520to%2520the%2520protection%2520of%2520activation%2520loop%2520phosphotyrosines%2520from%2520phosphatases%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26doi%3D10.1182%2Fblood.V122.21.2847.2847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tvorogov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liau, N. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dottore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hercus, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stomski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tergaonkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, A. F.</span></span> <span> </span><span class="NLM_article-title">Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">eaat3834</span> <span class="refDoi"> DOI: 10.1126/sciadv.aat3834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1126%2Fsciadv.aat3834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=30498775" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&author=D.+Tvorogovauthor=D.+Thomasauthor=N.+P.+D.+Liauauthor=M.+Dottoreauthor=E.+F.+Barryauthor=M.+Lathiauthor=W.+L.+Kanauthor=T.+R.+Hercusauthor=F.+Stomskiauthor=T.+P.+Hughesauthor=V.+Tergaonkarauthor=M.+W.+Parkerauthor=D.+M.+Rossauthor=R.+Majetiauthor=J.+J.+Babonauthor=A.+F.+Lopez&title=Accumulation+of+JAK+activation+loop+phosphorylation+is+linked+to+type+I+JAK+inhibitor+withdrawal+syndrome+in+myelofibrosis&doi=10.1126%2Fsciadv.aat3834"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat3834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat3834%26sid%3Dliteratum%253Aachs%26aulast%3DTvorogov%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DLiau%26aufirst%3DN.%2BP.%2BD.%26aulast%3DDottore%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DE.%2BF.%26aulast%3DLathi%26aufirst%3DM.%26aulast%3DKan%26aufirst%3DW.%2BL.%26aulast%3DHercus%26aufirst%3DT.%2BR.%26aulast%3DStomski%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DTergaonkar%26aufirst%3DV.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26aulast%3DMajeti%26aufirst%3DR.%26aulast%3DBabon%26aufirst%3DJ.%2BJ.%26aulast%3DLopez%26aufirst%3DA.%2BF.%26atitle%3DAccumulation%2520of%2520JAK%2520activation%2520loop%2520phosphorylation%2520is%2520linked%2520to%2520type%2520I%2520JAK%2520inhibitor%2520withdrawal%2520syndrome%2520in%2520myelofibrosis%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26doi%3D10.1126%2Fsciadv.aat3834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+structures+of+the+JAK2+pseudokinase+domain+and+the+pathogenic+mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies α-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0ljpoOna5dLS-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structures%2520of%2520the%2520JAK2%2520pseudokinase%2520domain%2520and%2520the%2520pathogenic%2520mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms</span>. <i>Hematol. Oncol. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.hoc.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=28673392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=627-642&author=S.+C.+Meyer&title=Mechanisms+of+resistance+to+JAK2+inhibitors+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.hoc.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms</span></div><div class="casAuthors">Meyer Sara C</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-642</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells.  JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone.  Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and functional, have been identified.  Resistance mutations have not been reported in MPN patients suggesting incomplete target inhibition.  Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors.  Additional combined therapy approaches are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsWLFM_lbR1VmfW6udTcc2eY8jp4ldF4iM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D&md5=195db657c3d8a32ffc83932047d37595</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520JAK2%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D31%26spage%3D627%26epage%3D642%26doi%3D10.1016%2Fj.hoc.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousoik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montazeri Aliabadi, H.</span></span> <span> </span><span class="NLM_article-title">Do we know jack about JAK? A closer look at JAK/STAT signaling pathway</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">287</span> <span class="refDoi"> DOI: 10.3389/fonc.2018.00287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.3389%2Ffonc.2018.00287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=30109213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ot1Crtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=E.+Bousoikauthor=H.+Montazeri+Aliabadi&title=Do+we+know+jack+about+JAK%3F+A+closer+look+at+JAK%2FSTAT+signaling+pathway&doi=10.3389%2Ffonc.2018.00287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">"Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway</span></div><div class="casAuthors">Bousoik Emira; Montazeri Aliabadi Hamidreza; Bousoik Emira</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">287</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in signal transduction initiated by a wide range of membrane receptors.  Among the proteins in this family JAK2 has been associated with important downstream proteins, including signal transducers and activators of transcription (STATs), which in turn regulate the expression of a variety of proteins involved in induction or prevention of apoptosis.  Therefore, the JAK/STAT signaling axis plays a major role in the proliferation and survival of different cancer cells, and may even be involved in resistance mechanisms against molecularly targeted drugs.  Despite extensive research focused on the protein structure and mechanisms of activation of JAKs, and signal transduction through these proteins, their importance in cancer initiation and progression seem to be underestimated.  This manuscript is an attempt to highlight the role of JAK proteins in cancer biology, the most recent developments in targeting JAKs, and the central role they play in intracellular cross-talks with other signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-a-G-lYtjX0NHe_gFldTbfW6udTcc2eY8jp4ldF4iM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ot1Crtw%253D%253D&md5=ecda3b0ddfbfbea2a1d47b87ec0b52e3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00287%26sid%3Dliteratum%253Aachs%26aulast%3DBousoik%26aufirst%3DE.%26aulast%3DMontazeri%2BAliabadi%26aufirst%3DH.%26atitle%3DDo%2520we%2520know%2520jack%2520about%2520JAK%253F%2520A%2520closer%2520look%2520at%2520JAK%252FSTAT%2520signaling%2520pathway%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26doi%3D10.3389%2Ffonc.2018.00287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karantanos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, A. R.</span></span> <span> </span><span class="NLM_article-title">The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2018.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.blre.2018.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29627078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=426-432&author=T.+Karantanosauthor=A.+R.+Moliterno&title=The+roles+of+JAK2+in+DNA+damage+and+repair+in+the+myeloproliferative+neoplasms%3A+Opportunities+for+targeted+therapy&doi=10.1016%2Fj.blre.2018.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy</span></div><div class="casAuthors">Karantanos, Theodoros; Moliterno, Alison R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-432</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK2V617F-pos. myeloproliferative neoplasms (MPN) serve as an excellent model for the study of genomic instability accumulation during cancer progression.  Recent studies highlight the implication of JAK2 activating mutations in the development of DNA damage via reactive oxygen species (ROS) prodn., replication stress induction and the accumulation of genomic instability via the increased degrdn. of p53 and acquisition of a "mutagenic" phenotype.  The accumulation of genomic instability and acquisition of mutations in crit. DNA damage repair (DDR) mediators appears to be implicated in the progression of JAK2V617F-pos. MPN.  On the other hand, JAK2 signaling normally induces DDR through activation of repair mediators such as Chk1, RAD51 and RECQL5.  These opposing effects on DNA integrity in the setting of JAK2V617F have significant clin. implications and have led to the introduction of novel combinational therapies for these diseases.  The inhibition of MDM2 with Nutlin-3 improves the efficacy of IFN-α via decreased p53 degrdn., the combination of hydroxyurea with Ruxolitinib, and their combination with PARP inhibitors have significant anti-tumor effects.  A better understanding of the implication of JAK2 in the development and repair of DNA damage can improve our understanding of the biol. of these neoplasms, meliorate the risk stratification of our patients and enrich our therapeutic armamentarium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5c2DIOJxzLVg90H21EOLACvtfcHk0ljpoOna5dLS-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVOisr8%253D&md5=67a26e3ed43b8ba4161694010cf40ce5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2018.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DKarantanos%26aufirst%3DT.%26aulast%3DMoliterno%26aufirst%3DA.%2BR.%26atitle%3DThe%2520roles%2520of%2520JAK2%2520in%2520DNA%2520damage%2520and%2520repair%2520in%2520the%2520myeloproliferative%2520neoplasms%253A%2520Opportunities%2520for%2520targeted%2520therapy%26jtitle%3DBlood%2520Rev.%26date%3D2018%26volume%3D32%26spage%3D426%26epage%3D432%26doi%3D10.1016%2Fj.blre.2018.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schieber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis in 2019: moving beyond JAK2 inhibition</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">74</span>, <span class="refDoi"> DOI: 10.1038/s41408-019-0236-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fs41408-019-0236-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=31511492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A280%3ADC%252BB3MrnvVWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=74&author=M.+Schieberauthor=J.+D.+Crispinoauthor=B.+Stein&title=Myelofibrosis+in+2019%3A+moving+beyond+JAK2+inhibition&doi=10.1038%2Fs41408-019-0236-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis in 2019: moving beyond JAK2 inhibition</span></div><div class="casAuthors">Schieber Michael; Crispino John D; Stein Brady</div><div class="citationInfo"><span class="NLM_cas:title">Blood cancer journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia.  The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as a primary driver of MF, supporting a rationale for JAK inhibition.  However, JAK inhibition alone is insufficient for long-term remission and offers modest, if any, disease-modifying effects.  Given this, there is great interest in identifying mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies.  This review outlines the latest discoveries in the biology of MF, discusses current clinical management of patients with MF, and summarizes the ongoing clinical trials that hope to change the landscape of MF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ21BNrHUZ1BWLFM_lbR1VmfW6udTcc2eYTUZp1G6d9N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrnvVWrtQ%253D%253D&md5=2b3376ccba1ca242430a5c5f6043a5e0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41408-019-0236-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41408-019-0236-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchieber%26aufirst%3DM.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26aulast%3DStein%26aufirst%3DB.%26atitle%3DMyelofibrosis%2520in%25202019%253A%2520moving%2520beyond%2520JAK2%2520inhibition%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2019%26volume%3D9%26spage%3D74%26doi%3D10.1038%2Fs41408-019-0236-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2721</span>– <span class="NLM_lpage">2730</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-11-395228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood-2011-11-395228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=22279053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFalt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2721-2730&author=A.+Tefferi&title=JAK+inhibitors+for+myeloproliferative+neoplasms%3A+clarifying+facts+from+myths&doi=10.1182%2Fblood-2011-11-395228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2721-2730</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis.  This is welcome news for those patients in whom such therapy is indicated and treatment benefit outweighs attendant risk.  The question is who are these patients, what should they expect in terms of both short-term effects and long-term impact, and why would they choose ruxolitinib over other JAK inhibitors that are freely available for use in a research setting.  Ruxolitinib and most other JAK inhibitors exert a salutary effect on constitutional symptoms and splenomegaly but have yet to produce histopathol. or cytogenetic remissions, reverse bone marrow fibrosis, or improve survival over best supportive care.  Furthermore, the palliative value of JAK inhibitors is diminished by notable side effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities, peripheral neuropathy, and hyperacute relapse of symptoms during treatment discontinuation.  Therefore, risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera, outside of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoABjGudqibSbVg90H21EOLACvtfcHk0lg8hvOCC-34SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFalt7s%253D&md5=441f2e6cd7b900b8ad9b385a742840b7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-395228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-395228%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DJAK%2520inhibitors%2520for%2520myeloproliferative%2520neoplasms%253A%2520clarifying%2520facts%2520from%2520myths%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2721%26epage%3D2730%26doi%3D10.1182%2Fblood-2011-11-395228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lg8hvOCC-34SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span> <span> </span><span class="NLM_article-title">Fedratinib becomes new option in myelofibrosis</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1332&author=C.+Caruso&title=Fedratinib+becomes+new+option+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaruso%26aufirst%3DC.%26atitle%3DFedratinib%2520becomes%2520new%2520option%2520in%2520myelofibrosis%26jtitle%3DCancer%2520Discov.%26date%3D2019%26volume%3D9%26spage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">FDA approves Eli Lilly’s baricitinib</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=460&author=A.+Mullard&title=FDA+approves+Eli+Lilly%E2%80%99s+baricitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA vaccines get another booster</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1pR5FbMQvVLVg90H21EOLACvtfcHk0liV8vT1XcyqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Sqtr3E&md5=025f07fb9a24835c5f349436f0372c10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520approves%2520Eli%2520Lilly%25E2%2580%2599s%2520baricitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2018%26volume%3D17%26spage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantschel, O.</span></span> <span> </span><span class="NLM_article-title">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fleu.2013.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23823659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=404-407&author=T.+Zhouauthor=S.+Georgeonauthor=R.+Moserauthor=D.+J.+Mooreauthor=A.+Caflischauthor=O.+Hantschel&title=Specificity+and+mechanism-of-action+of+the+JAK2+tyrosine+kinase+inhibitors+ruxolitinib+and+SAR302503+%28TG101348%29&doi=10.1038%2Fleu.2013.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)</span></div><div class="casAuthors">Zhou, T.; Georgeon, S.; Moser, R.; Moore, D. J.; Caflisch, A.; Hantschel, O.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">404-407</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-3vjA0n7DlLVg90H21EOLACvtfcHk0liV8vT1XcyqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gtbk%253D&md5=7dbebd3eac60c3dd19026c9e3d3d3204</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.205%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DGeorgeon%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DSpecificity%2520and%2520mechanism-of-action%2520of%2520the%2520JAK2%2520tyrosine%2520kinase%2520inhibitors%2520ruxolitinib%2520and%2520SAR302503%2520%2528TG101348%2529%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D404%26epage%3D407%26doi%3D10.1038%2Fleu.2013.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamontanara, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gencer, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzyk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantschel, O.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1834</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bbapap.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=23277196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1834&publication_year=2013&pages=1449-1459&author=A.+J.+Lamontanaraauthor=E.+B.+Gencerauthor=O.+Kuzykauthor=O.+Hantschel&title=Mechanisms+of+resistance+to+BCR-ABL+and+other+kinase+inhibitors&doi=10.1016%2Fj.bbapap.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span></div><div class="casAuthors">Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1834</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1449-1459</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  In this article, we are reviewing the mol. mechanisms that lead to kinase inhibitor resistance.  As the oncogenic BCR-ABL kinase is the target of the first approved small-mol. kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance.  We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients.  Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaBpN0j3KxrVg90H21EOLACvtfcHk0liV8vT1XcyqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D&md5=7706253e67a867b87ddadcec0bd5f972</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DLamontanara%26aufirst%3DA.%2BJ.%26aulast%3DGencer%26aufirst%3DE.%2BB.%26aulast%3DKuzyk%26aufirst%3DO.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520BCR-ABL%2520and%2520other%2520kinase%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2013%26volume%3D1834%26spage%3D1449%26epage%3D1459%26doi%3D10.1016%2Fj.bbapap.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almqvist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Molina, D.</span></span> <span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundbackauthor=P.+Nordlundauthor=D.+Martinez+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0li1uHU42I32Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundback%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ember, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranfill, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0568-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1158%2F1535-7163.MCT-16-0568-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=28336808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1054-1067&author=S.+W.+Emberauthor=Q.+T.+Lambertauthor=N.+Berndtauthor=S.+Gunawanauthor=M.+Ayazauthor=M.+Tauroauthor=J.+Y.+Zhuauthor=P.+J.+Cranfillauthor=P.+Greningerauthor=C.+C.+Lynchauthor=C.+H.+Benesauthor=H.+R.+Lawrenceauthor=G.+W.+Reutherauthor=N.+J.+Lawrenceauthor=E.+Schonbrunn&title=Potent+dual+BET+bromodomain-kinase+inhibitors+as+value-added+multitargeted+chemical+probes+and+cancer+therapeutics&doi=10.1158%2F1535-7163.MCT-16-0568-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics</span></div><div class="casAuthors">Ember, Stuart W.; Lambert, Que T.; Berndt, Norbert; Gunawan, Steven; Ayaz, Muhammad; Tauro, Marilena; Zhu, Jin-Yi; Cranfill, Paula J.; Greninger, Patricia; Lynch, Conor C.; Benes, Cyril H.; Lawrence, Harshani R.; Reuther, Gary W.; Lawrence, Nicholas J.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1054-1067</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers.  Using the chem. scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1.  Lead compds. showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm.  Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1.  Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing.  Combined, our findings indicate promising potential of these agents as novel chem. probes and cancer therapeutics.  Mol Cancer Ther; 16(6); 1054-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFXcj0XbzGLVg90H21EOLACvtfcHk0li1uHU42I32Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht74%253D&md5=1c0a838978c931fd8ad148a6696bda26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0568-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0568-T%26sid%3Dliteratum%253Aachs%26aulast%3DEmber%26aufirst%3DS.%2BW.%26aulast%3DLambert%26aufirst%3DQ.%2BT.%26aulast%3DBerndt%26aufirst%3DN.%26aulast%3DGunawan%26aufirst%3DS.%26aulast%3DAyaz%26aufirst%3DM.%26aulast%3DTauro%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DCranfill%26aufirst%3DP.%2BJ.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DC.%2BC.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DPotent%2520dual%2520BET%2520bromodomain-kinase%2520inhibitors%2520as%2520value-added%2520multitargeted%2520chemical%2520probes%2520and%2520cancer%2520therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1054%26epage%3D1067%26doi%3D10.1158%2F1535-7163.MCT-16-0568-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quentmeier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaborski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H. G.</span></span> <span> </span><span class="NLM_article-title">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1038%2Fsj.leu.2404081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=16408098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Kjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=471-476&author=H.+Quentmeierauthor=R.+A.+MacLeodauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=JAK2+V617F+tyrosine+kinase+mutation+in+cell+lines+derived+from+myeloproliferative+disorders&doi=10.1038%2Fsj.leu.2404081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span></div><div class="casAuthors">Quentmeier, H.; MacLeod, R. A. F.; Zaborski, M.; Drexler, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mutation in the JH2 pseudokinase domain of the Janus kinase 2 gene (JAK2 V617F) has been described in chronic myeloproliferative disorders (MPD).  We screened 79 acute myeloid leukemia (AML) cell lines and found five pos. for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS.  While SET-2 expressed both mutant (mu) and wild-type (wt) JAK2, remaining positives carried homo-/hemizygous JAK2 mutations.  Microsatellite anal. confirmed losses of heterozygosity (LOH) affecting the JAK2 region on chromosome 9p in MB-02, MUTZ-8 and UKE-1, but also in HEL, the only JAK2mu cell line lacking any reported MPD/MDS history.  All five JAK2mu cell lines displayed cytogenetic hallmarks of MDS, namely losses of 5q or 7q, remarkably in 4/5 cases affecting both chromosomes.  Our combined FISH and microsatellite anal. uncovered a novel mechanism to supplement mitotic recombination previously proposed to explain JAK2 LOH, namely chromosome deletion with/without selective JAK2mu amplification.  Confirming the importance of the mutated JAK2 protein for growth and prevention of apoptosis, JAK2mu cell lines displayed higher sensitivities to JAK2 inhibition than JAK2wt cell lines.  In summary, JAK2 V617F cell lines, derived from patients with history of MPD/MDS, represent novel research tools for elucidating the pathobiol. of this JAK2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbWLZTI7h7Vg90H21EOLACvtfcHk0lgyZqeyUxhj9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Kjtbo%253D&md5=b75412e3ac608626fac7666b0e9a9a2c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404081%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DJAK2%2520V617F%2520tyrosine%2520kinase%2520mutation%2520in%2520cell%2520lines%2520derived%2520from%2520myeloproliferative%2520disorders%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fsj.leu.2404081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. G.</span></span> <span> </span><span class="NLM_article-title">c-Src binds to the cancer drug Ruxolitinib with an active conformation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e106225</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0106225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1371%2Fjournal.pone.0106225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25197973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOju7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=Y.+Duanauthor=L.+Chenauthor=Y.+Chenauthor=X.+G.+Fan&title=c-Src+binds+to+the+cancer+drug+Ruxolitinib+with+an+active+conformation&doi=10.1371%2Fjournal.pone.0106225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src binds to the cancer drug Ruxolitinib with an active conformation</span></div><div class="casAuthors">Duan, Yankun; Chen, Lin; Chen, Yongheng; Fan, Xue-Gong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e106225/1-e106225/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms.  In addn., Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.  There is no structural information of Ruxolitinib binding to any kinase.  In this paper, we detd. the crystal structure of c-Src kinase domain in complex of Ruxolitinib at a resoln. of 2.26 Å.  C-Src kinase domain adopts the DFG-in active conformation upon Ruxolitinib binding, indicating Ruxolitinib is a type I inhibitor for c-Src.  Ruxolitinib forms two hydrogen bonds with Met341, a water-mediated hydrogen bond with Thr338 and a no. of van der Waals contacts with c-Src.  Ruxolitinib was then docked into the ligand-binding pocket of a previously solved JAK1 structure.  From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.  Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnUlK89E7xArVg90H21EOLACvtfcHk0lgyZqeyUxhj9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOju7bK&md5=6786a81e8bef0d881523902144b833b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0106225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0106225%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DX.%2BG.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520Ruxolitinib%2520with%2520an%2520active%2520conformation%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0106225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lj_g2IksfOXtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightle, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span> <span> </span><span class="NLM_article-title">Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.pep.2009.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.pep.2009.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=19781647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2010&pages=54-63&author=T.+Hallauthor=T.+L.+Emmonsauthor=J.+E.+Chrencikauthor=J.+A.+Gormleyauthor=R.+A.+Weinbergauthor=J.+W.+Leoneauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+F.+Schindlerauthor=J.+E.+Dayauthor=J.+M.+Williamsauthor=J.+R.+Kieferauthor=S.+A.+Lightleauthor=M.+S.+Harrisauthor=S.+Guruauthor=H.+D.+Fischerauthor=A.+G.+Tomasselli&title=Expression%2C+purification%2C+characterization+and+crystallization+of+non-+and+phosphorylated+states+of+JAK2+and+JAK3+kinase+domain&doi=10.1016%2Fj.pep.2009.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain</span></div><div class="casAuthors">Hall, Troii; Emmons, Thomas L.; Chrencik, Jill E.; Gormley, Jennifer A.; Weinberg, Robin A.; Leone, Joseph W.; Hirsch, Jeffrey L.; Saabye, Matthew J.; Schindler, John F.; Day, Jacqueline E.; Williams, Jennifer M.; Kiefer, James R.; Lightle, Sandra A.; Harris, Melissa S.; Guru, Siradanahalli; Fischer, H. David; Tomasselli, Alfredo G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression & Purification</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus-assocd. kinases (JAKs) play crit. roles in cytokine signaling, and have emerged as viable therapeutic targets in inflammation and oncol. related diseases.  To date, targeting JAK proteins with highly selective inhibitor compds. have remained elusive.  We have expressed the active kinase domains for both JAK2 and JAK3 and devised purifn. protocols to resolve the non-, mono- (Y1007) and diphosphorylated (Y1007 and Y1008) states of JAK2 and non- and monophosphorylated states of JAK3 (Y980).  An optimal purified protein yield of 20, 29 and 69 mg per 20 L cell culture was obtained for the three JAK2 forms, resp., and 12.2 and 2.3 mg per 10 L fermn. for the two JAK3 forms allowing detailed biochem. and biophys. studies.  To monitor the purifn. process we developed a novel HPLC activity assay where a sequential order of phosphorylation was obsd. whereby the first tyrosine residue was completely phosphorylated prior to phosphorylation of the tandem tyrosine residue.  A Caliper-based microfluidics assay was used to det. the kinetic parameters (K m and kcat) for each phosphorylated state, showing that monophosphorylated (Y1007) JAK2 enzyme activity increased 9-fold over that of the nonphosphorylated species, and increased an addnl. 6-fold for the diphosphorylated (Y1007/Y1008) species, while phosphorylation of JAK3 resulted in a negligible increase in activity.  Moreover, crystal structures have been generated for each isolated state of JAK2 and JAK3 with resolns. better than 2.4 Å.  The generation of these reagents has enabled kinetic and structural characterization to inform the design of potent and selective inhibitors of the JAK family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb5gEwPDT4LVg90H21EOLACvtfcHk0lj_g2IksfOXtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrtLjF&md5=ae884695b3fb546edbed762d65b74ad3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pep.2009.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pep.2009.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DT.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLightle%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DM.%2BS.%26aulast%3DGuru%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26atitle%3DExpression%252C%2520purification%252C%2520characterization%2520and%2520crystallization%2520of%2520non-%2520and%2520phosphorylated%2520states%2520of%2520JAK2%2520and%2520JAK3%2520kinase%2520domain%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2010%26volume%3D69%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.pep.2009.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2809</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bmcl.2015.04.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=25987372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2809-2812&author=K.+Zimmermannauthor=X.+Sangauthor=H.+A.+Mastalerzauthor=W.+L.+Johnsonauthor=G.+Zhangauthor=Q.+Liuauthor=D.+Battauthor=L.+J.+Lombardoauthor=D.+Vyasauthor=G.+L.+Trainorauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=M.+M.+Gottardisauthor=J.+Lippyauthor=J.+Khanauthor=J.+S.+Sackauthor=A.+V.+Purandare&title=9H-Carbazole-1-carboxamides+as+potent+and+selective+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors</span></div><div class="casAuthors">Zimmermann, Kurt; Sang, Xiaopeng; Mastalerz, Harold A.; Johnson, Walter L.; Zhang, Guifen; Liu, Qingjie; Batt, Douglas; Lombardo, Louis J.; Vyas, Dinesh; Trainor, George L.; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; Gottardis, Marco M.; Lippy, Jonathan; Khan, Javed; Sack, John S.; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2809-2812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed.  Optimization for JAK family selectivity led to compds. I and II, with greater than 45-fold selectivity for JAK2 over all other members of the JAK kinase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ4DLKQOU6vLVg90H21EOLACvtfcHk0lj4P366nT_PXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGktr0%253D&md5=bbe6542426b0da0ae8938cd55a395b3c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.101%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DMastalerz%26aufirst%3DH.%2BA.%26aulast%3DJohnson%26aufirst%3DW.%2BL.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DVyas%26aufirst%3DD.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3D9H-Carbazole-1-carboxamides%2520as%2520potent%2520and%2520selective%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2809%26epage%3D2812%26doi%3D10.1016%2Fj.bmcl.2015.04.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.+B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfo+namide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lj4P366nT_PXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfo%2520namide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6176</span>– <span class="NLM_lpage">6193</span>, <span class="refDoi"> DOI: 10.1021/jm300628c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+Devossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavailable+JAK1+inhibitors+with+selectivity+over+JAK2&doi=10.1021%2Fjm300628c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Mendonca, Rohan; Balazs, Mercedesz; Barrett, Kathy; Bergeron, Philippe; Blair, Wade S.; Chang, Christine; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Hamman, Chris; Hanan, Emily J.; Harstad, Eric; Hewitt, Peter R.; Hurley, Christopher A.; Jin, Tian; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Kulagowski, Janusz J.; Labadie, Sharada; Liao, Jiangpeng; Liimatta, Marya; Lin, Zhonghua; Lupardus, Patrick J.; Maxey, Robert J.; Murray, Jeremy M.; Pulk, Rebecca; Rodriguez, Madeleine; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Xiao, Ling; Xiao, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6176-6193</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the discovery of the C-2 Me substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.  The C-2 Me substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compd. 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochem. and cell-based assays, resp.).  Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated.  Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20).  Details of the biol. characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclin. in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogQqQMRvwKbVg90H21EOLACvtfcHk0lgjfAvRaixsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D&md5=8c57a4cb02fc245ed12f6f4efdb82318</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDevoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193%26doi%3D10.1021%2Fjm300628c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span>; <span class="NLM_string-name">Zhu, H.</span>; <span class="NLM_string-name">Wu, J.</span>; <span class="NLM_string-name">Tian, G.</span></span> <span> </span><span class="NLM_article-title">Intermediate of JAK inhibitor and preparation method thereof</span>.  <i>China patent</i> <span class="NLM_year">2018</span><b>,</b> <span class="NLM_patent">CN107759623A</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+Cao&author=H.+Zhu&author=J.+Wu&author=G.+Tian&title=Intermediate+of+JAK+inhibitor+and+preparation+method+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DB.%26atitle%3DIntermediate%2520of%2520JAK%2520inhibitor%2520and%2520preparation%2520method%2520thereof%26jtitle%3DChina%2520patent%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knouse, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuest, W. M.</span></span> <span> </span><span class="NLM_article-title">Diverted total synthesis of promysalin analogs demonstrates that an iron-binding motif is responsible for its narrow-spectrum antibacterial activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5836</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b03373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b03373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=5833-5836&author=A.+D.+Steeleauthor=C.+E.+Keohaneauthor=K.+W.+Knouseauthor=S.+E.+Rossiterauthor=S.+J.+Williamsauthor=W.+M.+Wuest&title=Diverted+total+synthesis+of+promysalin+analogs+demonstrates+that+an+iron-binding+motif+is+responsible+for+its+narrow-spectrum+antibacterial+activity&doi=10.1021%2Fjacs.6b03373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diverted Total Synthesis of Promysalin Analogs Demonstrates That an Iron-Binding Motif Is Responsible for Its Narrow-Spectrum Antibacterial Activity</span></div><div class="casAuthors">Steele, Andrew D.; Keohane, Colleen E.; Knouse, Kyle W.; Rossiter, Sean E.; Williams, Sierra J.; Wuest, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5836</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Promysalin (I) is a species-specific Pseudomonad metabolite with unique bioactivity.  To better understand the mode of action of this natural product, we synthesized 16 analogs utilizing diverted total synthesis (DTS).  Our analog studies revealed that the bioactivity of promysalin is sensitive to changes within its hydrogen bond network whereby alteration has drastic biol. consequences.  The DTS library not only yielded three analogs that retained potency but also provided insights that resulted in the identification of a previously unknown ability of promysalin to bind iron.  These findings coupled with previous observations hint at a complex multifaceted role of the natural product within the rhizosphere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL9HadENBaPrVg90H21EOLACvtfcHk0ljsSulM4xpR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsLk%253D&md5=79c9be41f340fe1a194f8e05c1a1e19e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b03373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b03373%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DA.%2BD.%26aulast%3DKeohane%26aufirst%3DC.%2BE.%26aulast%3DKnouse%26aufirst%3DK.%2BW.%26aulast%3DRossiter%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DWuest%26aufirst%3DW.%2BM.%26atitle%3DDiverted%2520total%2520synthesis%2520of%2520promysalin%2520analogs%2520demonstrates%2520that%2520an%2520iron-binding%2520motif%2520is%2520responsible%2520for%2520its%2520narrow-spectrum%2520antibacterial%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D5833%26epage%3D5836%26doi%3D10.1021%2Fjacs.6b03373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljsSulM4xpR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=10.1016%2Fj.bmcl.2018.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=29945795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2636-2640&author=L.+Yaoauthor=P.+M.+Ramanujuluauthor=A.+Poulsenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Merging+of+ruxolitinib+and+vorinostat+leads+to+highly+potent+inhibitors+of+JAK2+and+histone+deacetylase+6+%28HDAC6%29&doi=10.1016%2Fj.bmcl.2018.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span></div><div class="casAuthors">Yao, Lianbin; Ramanujulu, Pondy Murugappan; Poulsen, Anders; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2636-2640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of more than one pathway in a cancer cell with a single mol. could result in better therapies with less complex dosing regimens.  In this work multi-component ligands have been prepd. by joining together key pharmacophores of two different enzyme inhibitors in a way which increases potency against the individual pathways.  Selective JAK1/2 inhibitor, ruxolitinib (3), and pan-HDAC inhibitor vorinostat (4) were linked together by a single nitrogen atom to create a new series of compds. with very potent JAK2 and HDAC6 inhibition with selectivity against HDAC1.  A preferred compd., I, had unprecedented sub-nanomolar JAK2 potency with an IC50 of 41 pM and a sub-nanomolar IC50 against HDAC6 of 200 pM.  Binding models show a good fit into both JAK2 and HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3j4Hop3jqrVg90H21EOLACvtfcHk0lhNZFrYHujY1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M&md5=78776f7cd6ac7384c701edd2fd4a6940</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DMerging%2520of%2520ruxolitinib%2520and%2520vorinostat%2520leads%2520to%2520highly%2520potent%2520inhibitors%2520of%2520JAK2%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2636%26epage%3D2640%26doi%3D10.1016%2Fj.bmcl.2018.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akri-Topoulou-Zanze, I.</span>; <span class="NLM_string-name">Wakefield, B. D.</span>; <span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Turner, S. C.</span>; <span class="NLM_string-name">Gasiecki, A. F.</span>; <span class="NLM_string-name">Gracias, V. J.</span>; <span class="NLM_string-name">Sarris Kathy, A.</span>; <span class="NLM_string-name">Kalvin, D. M.</span>; <span class="NLM_string-name">Michmerhuizen, M. J.</span>; <span class="NLM_string-name">Shuai, Q.</span>; <span class="NLM_string-name">Patel, J. R.</span>; <span class="NLM_string-name">Bakker, M.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Johnson, E. T.</span>; <span class="NLM_string-name">Kovar, P. J.</span>; <span class="NLM_string-name">Djuric, S. W.</span>; <span class="NLM_string-name">Long, A. J.</span>; <span class="NLM_string-name">Vasudevan, A.</span>; <span class="NLM_string-name">George, D.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">St. John Moore, N.</span>; <span class="NLM_string-name">Hobson, A. D.</span>; <span class="NLM_string-name">Woods, K. W.</span>; <span class="NLM_string-name">Miyashiro, J. M.</span>; <span class="NLM_string-name">Swann, S. L. J.</span>; <span class="NLM_string-name">Penning, T. D.</span></span> <span> </span><span class="NLM_article-title">5-Substituted Indazoles as Kinase Inhibitors</span>. US patent <span class="NLM_year">2014</span>, <span class="NLM_patent">8,648,069B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=I.+Akri-Topoulou-Zanze&author=B.+D.+Wakefield&author=H.+Mack&author=S.+C.+Turner&author=A.+F.+Gasiecki&author=V.+J.+Gracias&author=A.+Sarris+Kathy&author=D.+M.+Kalvin&author=M.+J.+Michmerhuizen&author=Q.+Shuai&author=J.+R.+Patel&author=M.+Bakker&author=N.+Teusch&author=E.+T.+Johnson&author=P.+J.+Kovar&author=S.+W.+Djuric&author=A.+J.+Long&author=A.+Vasudevan&author=D.+George&author=L.+Wang&author=B.+Li&author=N.+St.+John+Moore&author=A.+D.+Hobson&author=K.+W.+Woods&author=J.+M.+Miyashiro&author=S.+L.+J.+Swann&author=T.+D.+Penning&title=5-Substituted+Indazoles+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAkri-Topoulou-Zanze%26aufirst%3DI.%26atitle%3D5-Substituted%2520Indazoles%2520as%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Liu, P.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Metcalf, B. W.</span>; <span class="NLM_string-name">Meloni, D.</span>; <span class="NLM_string-name">Pan, Y.</span>; <span class="NLM_string-name">Xia, M.</span>; <span class="NLM_string-name">Li, M.</span>; <span class="NLM_string-name">Yue, T.-Y.</span>; <span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing JAK Inhibitors and Related Compounds</span>. US patent <span class="NLM_year">2013</span>, <span class="NLM_patent">US8,410,265B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Zhou&author=P.+Liu&author=Q.+Lin&author=B.+W.+Metcalf&author=D.+Meloni&author=Y.+Pan&author=M.+Xia&author=M.+Li&author=T.-Y.+Yue&author=J.+D.+Rodgers&author=H.+Wang&title=Processes+for+Preparing+JAK+Inhibitors+and+Related+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DProcesses%2520for%2520Preparing%2520JAK%2520Inhibitors%2520and%2520Related%2520Compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akri-Topoulou-Zanze, I.</span>; <span class="NLM_string-name">Wakefield, B. D.</span>; <span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Turner, S. C.</span>; <span class="NLM_string-name">Gasiecki, A. F.</span>; <span class="NLM_string-name">Gracias, V. J.</span>; <span class="NLM_string-name">Kathy, S.</span>; <span class="NLM_string-name">Kalvin, D. M.</span>; <span class="NLM_string-name">Michmerhuizen, M. J.</span>; <span class="NLM_string-name">Shuai, Q.</span>; <span class="NLM_string-name">Patel, J. R.</span>; <span class="NLM_string-name">Bakker, M.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Johnson, E. T.</span>; <span class="NLM_string-name">Kovar, P. J.</span>; <span class="NLM_string-name">Djuric, S. W.</span>; <span class="NLM_string-name">Long, A. J.</span>; <span class="NLM_string-name">Vasude-Van, A.</span>; <span class="NLM_string-name">Hobson, A.</span>; <span class="NLM_string-name">St. John Moore, N.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">George, D.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Frank, K.</span></span> <span> </span><span class="NLM_article-title">5-Heteroaryl Substituted Indazoles as Kinase Inhibitors</span>. PCT patent application <span class="NLM_year">2013</span>, <span class="NLM_patent">WO2008/154241A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=I.+Akri-Topoulou-Zanze&author=B.+D.+Wakefield&author=H.+Mack&author=S.+C.+Turner&author=A.+F.+Gasiecki&author=V.+J.+Gracias&author=S.+Kathy&author=D.+M.+Kalvin&author=M.+J.+Michmerhuizen&author=Q.+Shuai&author=J.+R.+Patel&author=M.+Bakker&author=N.+Teusch&author=E.+T.+Johnson&author=P.+J.+Kovar&author=S.+W.+Djuric&author=A.+J.+Long&author=A.+Vasude-Van&author=A.+Hobson&author=N.+St.+John+Moore&author=L.+Wang&author=D.+George&author=B.+Li&author=K.+Frank&title=5-Heteroaryl+Substituted+Indazoles+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAkri-Topoulou-Zanze%26aufirst%3DI.%26atitle%3D5-Heteroaryl%2520Substituted%2520Indazoles%2520as%2520Kinase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span>; <span class="NLM_string-name">Lawrence, N. J.</span>; <span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">BRD4-JAK2 Inhibitors</span>. PCT patent application <span class="NLM_year">2020</span>, <span class="NLM_patent">WO2020/051572</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Schonbrunn&author=N.+J.+Lawrence&author=H.+R.+Lawrence&title=BRD4-JAK2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DBRD4-JAK2%2520Inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span>; <span class="NLM_string-name">Lawrence, N. J.</span>; <span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">Potent Dual BRD4-Kinase Inhibitors as Cancer Therapeutics</span>.  <i>US patent</i> <span class="NLM_year">2018</span><b>,</b> <span class="NLM_patent">US10,106,507B2</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Schonbrunn&author=N.+J.+Lawrence&author=H.+R.+Lawrence&title=Potent+Dual+BRD4-Kinase+Inhibitors+as+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DPotent%2520Dual%2520BRD4-Kinase%2520Inhibitors%2520as%2520Cancer%2520Therapeutics%26jtitle%3DUS%2520patent%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i55"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01952">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11431"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01952?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01952</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_001.csv">CSV</a>)</p></li><li><p class="inline">Supplementary figures, schematics and tables (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_001.csv">jm0c01952_si_001.csv (1.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01952/suppl_file/jm0c01952_si_002.pdf">jm0c01952_si_002.pdf (2.49 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01952&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01952" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01952" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797b07caf6d94a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
